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Reperfusion injury, the paradoxical tissue response that is manifested by blood ﬂow-deprived and
oxygen-starved organs following the restoration of blood ﬂow and tissue oxygenation, has been a focus
of basic and clinical research for over 4-decades. While a variety of molecular mechanisms have been
proposed to explain this phenomenon, excess production of reactive oxygen species (ROS) continues to
receive much attention as a critical factor in the genesis of reperfusion injury. As a consequence, con-
siderable effort has been devoted to identifying the dominant cellular and enzymatic sources of excess
ROS production following ischemia-reperfusion (I/R). Of the potential ROS sources described to date,
xanthine oxidase, NADPH oxidase (Nox), mitochondria, and uncoupled nitric oxide synthase have gained
a status as the most likely contributors to reperfusion-induced oxidative stress and represent priority
targets for therapeutic intervention against reperfusion-induced organ dysfunction and tissue damage.
Although all four enzymatic sources are present in most tissues and are likely to play some role in
reperfusion injury, priority and emphasis has been given to speciﬁc ROS sources that are enriched in
certain tissues, such as xanthine oxidase in the gastrointestinal tract and mitochondria in the metabo-
lically active heart and brain. The possibility that multiple ROS sources contribute to reperfusion injury in
most tissues is supported by evidence demonstrating that redox-signaling enables ROS produced by one
enzymatic source (e.g., Nox) to activate and enhance ROS production by a second source (e.g., mi-
tochondria). This review provides a synopsis of the evidence implicating ROS in reperfusion injury, the
clinical implications of this phenomenon, and summarizes current understanding of the four most fre-
quently invoked enzymatic sources of ROS production in post-ischemic tissue.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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It is well known that an impairment of blood ﬂow (ischemia)
can result in tissue injury and organ dysfunction, with duration
and severity of the ischemic insult determining the reversibility of
the injury response and ultimate survival of the tissue [1–4]. Is-
chemic tissue injury is generally attributed to a profound and
lengthy period of tissue hypoxia and the consequent depletion of
cellular ATP. It has long been appreciated that survival of ischemic
tissue can be ensured by the timely restoration of blood ﬂow
(reperfusion), which should serve to minimize the magnitude of
the hypoxic insult, allow for the replenishment of cellular ATP
levels, re-establish ionic balance within the cell, and ultimately
result in full restoration of organ function. However, the pre-
dictable beneﬁcial inﬂuence of early reperfusion on tissue recovery
following ischemia was challenged in the 1970s by reports de-
scribing a paradoxical enhancement of the injury response fol-
lowing reperfusion (or reoxygenation) of ischemic (or hypoxic)
tissue [5,6]. This led to the proposal by Hearse et al. [6] that the
sudden reintroduction of molecular oxygen to energy- (and oxy-
gen-) starved tissue results in a unique type of injury response that
is not manifested during the period of hypoxic stress. The dis-
covery of this reoxygenation-dependent injury response, which is
now commonly called “reperfusion injury”, opened a new ﬁeld of
scientiﬁc investigation that has grown rapidly and consistently to
this day (Fig. 1).
Since its inception, the concept of reperfusion injury has stea-
dily gained attention as an underlying component of a variety of
human diseases and disorders, and it has received similar notice in
the ﬁeld of veterinary medicine [7,8]. As a consequence, much
attention has been devoted to deﬁning the molecular and cellular
basis of the unique injury response that results when ischemic
tissues are reperfused [1,2,9]. In the early 1980s, oxygen-derived
free radicals (now more commonly referred to as reactive oxygen
species, ROS) were proposed as potential mediators of reperfusion
injury. The premise that highly reactive and unstable molecules
like ROS could account for reperfusion injury was quickly em-
braced, in large part because it was consistent with the observa-
tion that the injury response was dependent on the reintroduction
of molecular oxygen. Furthermore, evidence was soon provided to
support the notion that, with reperfusion of ischemic tissue, an
imbalance is created between the rate of generation of ROS and
the tissue's ability to detoxify these reactive species [10,11]. In the
35 years since ROS were ﬁrst implicated in reperfusion injury, the
molecular basis and pathophysiological signiﬁcance of this ROS-Fig. 1. Publication frequency of articles dealing with ischemia-reperfusion injury
from 1970 through 2014. Based on PubMed search (June, 2015) using search term
“ischemia-reperfusion injury” or “reperfusion injury”.dependent response has been extensively studied, providing new
insights into the enzymatic and cellular sources of the ROS, the
magnitude of ROS production elicited by reperfusion (reoxygena-
tion), and how ROS production ultimately leads to tissue injury.
This review addresses how the concept of ROS-mediated re-
perfusion injury has evolved over the past 3-plus decades and it
examines the evidence that has accumulated over this period to
support or refute the existence of ROS-mediated reperfusion injury
in different organ systems, as well as its relevance to different
pathological states.2. Reperfusion induced organ dysfunction/injury
The continued expansion of the scientiﬁc literature on ische-
mia-reperfusion (I/R) injury over the past 40 years is likely a re-
ﬂection of several factors, including the implication of this me-
chanism of tissue injury in a growing list of organs, the develop-
ment and use of in vitro models that mimic the condition of hy-
poxia followed by reoxygenation (H/R), and the implication of
reperfusion injury in an expanding list of human diseases and
clinical conditions. Reperfusion injury has been described and
studied in most organs in the body, with reports describing this
mechanism of injury in the heart [12], brain [13], skeletal muscle
[14], skin [15], lung [16], eye [17], spinal cord [18], intestine [19],
liver [20], kidney [21], uterus [22], ovary [23], testicle [24], penis
[25], and joints [26]. While this assortment of tissues shares some
characteristic features of the injury response to I/R, such as ne-
crosis, apoptosis, impaired microvascular function, and edema,
there is considerable diversity in the responses between tissues
that reﬂect the unique functional properties of the affected organ.
Some examples of these unique functional responses to I/R include
arrhythmias and stunning (transient depression of cardiac con-
tractility) for the heart [27,28], behavioral deﬁcits for brain [13],
paralysis for spinal cord [18], depressed motility and bacterial
translocation (with endotoxemia) for intestine [29], visual im-
pairment and blindness for eye [30], depressed glomerular ﬁltra-
tion rate and proteinuria for kidney [21], and infertility for testes
and ovaries [23,24].
In vitro models have proven to be useful for determining the
responses of single cell populations to I/R [31–34]. These models,
which expose isolated, puriﬁed cell populations to hypoxia (or
anoxia) and reoxygenation (H/R and A/R), have capitalized on the
creation of well-deﬁned and precisely controlled conditions to
determine whether the tissue injury responses elicited by I/R
in vivo can be recapitulated by single cell populations. While the
conditions used to simulate I/R in vitro are arguably artiﬁcial due
to the absence of other relevant cell populations and non-phy-
siological environmental conditions (e.g., pO2, pH), the in vitro
models have shown a remarkable level of consistency in re-
producing the phenotypic responses of tissues to I/R [32]. Simila-
rities in the in vitro and in vivo responses to I/R (H/R) have been
demonstrated using cardiac myocytes [35], intestinal enterocytes
[36], alveolar epithelium [34], neurons [37], hepatocytes [38],
adipocytes [39], and arterial grafts [40]. Endothelial cell (EC)
monolayers subjected to H/R have proven to be extraordinarily
accurate in simulating the diverse microvascular alterations that
are elicited by H/R, including (1) an enhanced production of ROS
[41], (2) increased expression of adhesion molecules with a con-
sequent increase in the adhesivity of EC to leukocytes (neutrophils
and T-lymphocytes) [42,43], (3) diminished EC barrier function
[44], and (4) the development of a procoagulant/prothrombotic
phenotype [45] (Fig. 2). Indeed, the adhesive interactions between
post-hypoxic EC monolayers and blood cells, such as neutrophils
and T-lymphocytes, have been extensively used as a surrogate for
the inﬂammatory responses elicited by I/R [33,42]. Growing
Fig. 2. Responses of vascular endothelial cells (EC) to anoxia/reoxygenation (A/R) or hypoxia/reoxygenation (H/R). (Panel A) Radical production by human aortic EC exposed
to 60 min anoxia and 10 min reoxygenation. Measurements derived from electron paramagnetic resonance using the spin trap 5,5-dimethyl-1-pyrroline N-oxide (DMPO).
The large signal detected after reoxygenation was not evident when the EC were treated with either superoxide dismutase (SOD) or oxypurinol (Oxy). Data from Zweier et al.
[110]. (Panel B) Albumin permeability across monolayers of bovine pulmonary artery EC exposed to 90 min hypoxia, with or without 90 reoxygenation. While hypoxia per se
did not increase monolayer permeability, H/R elicited a signiﬁcant increase. The H/R-induced permeability response was prevented by pretreatment with either SOD or
oxypurinol (Oxy). Data from Inauen et al. [44]. (Panel C) Neutrophil (PMN) adhesion response on human umbilical vein endothelial cells (HUVEC) exposed to 60 min anoxia,
followed by 30–600 min reoxygenation. A biphasic adhesion response was noted with an initial peak (phase 1) at 30 min and a later peak (phase 2) at 240 min. (Panel D)
Biphasic increases in endothelial expression of P- and E-selectin on HUVEC exposed to A/R (as described for Panel C). (Panel E) PMN adhesion on HUVEC monolayers exposed
to A/R (as per Panel C) following treatment with a blocking antibody to either P-selectin (anti-P-sel) or E-selectin (anti-E-sel), SOD or Oxy. Data in Panels C–E from Ichikawa
et al. [42].
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thogenesis of I/R injury has led to efforts to increase the com-
plexity of the in vitro models through the development of multi-
cellular co-culture systems, such as a neurovascular model com-
prised of co-cultured neurons, astrocytes, and cerebral micro-
vascular EC to simulate the blood–brain barrier (BBB) [46]. The
neurovascular unit model exhibits a more robust barrier function
(reduced permeability) compared to EC monolayers and this more
restrictive barrier is compromised to a greater degree in response
to H/R [46], suggesting that having neurons and astrocytes as
neighbors of EC more adequately simulates the properties of the
intact BBB as well as its response to I/R. Perhaps the most tangible
beneﬁt of the in vitro models of I/R injury has been their utility in
dissecting the complex array of signaling molecules that underlie
the diverse cellular changes and injury responses that are ulti-
mately manifested in postischemic tissue [47,48]. This reductionist
approach to the study of I/R injury has contributed to the con-
tinued growth and interest in this ﬁeld of investigation.
It is now generally accepted that reperfusion injury has the
potential to jeopardize the functional recovery of patients that
experience transient disruption of blood perfusion to a single tis-
sue or multiple organs, either as a consequence of a medical/sur-
gical procedure (e.g., organ transplantation and thrombolytictherapy) or in response to a disease process (e.g., acute kidney
injury, neonatal necrotizing enterocolitis) (Table 1) [1,49]. Condi-
tions that are not traditionally considered to be associated with
transient episodes of ischemia and/or hypoxia, such sickle cell
disease [50], osteoarthritis [26], and Alzheimer's disease [51], are
now receiving attention as a clinical manifestation of I/R injury.
The periodic episodes of painful vasoocclusion and reperfusion
that is characteristic of a sickle cell crisis have been likened to I/R
injury [52]. Similarly, reperfusion injury has been implicated in the
pathophysiology of obstructive sleep apnea, a condition associated
with transient periods of airway obstruction (and hypoxia) fol-
lowed by reoxygenation [53]. Finally, there is also growing evi-
dence in animal models that hepatic I/R promotes the metastasis
of cancerous cells to the liver from the pancreas [54] and color-
ectum [55]. While reperfusion injury is being assigned a role in the
pathogenesis of a growing list of clinical conditions, the relative
importance of reperfusion-dependent vs reperfusion-independent
mechanisms in the overall morbidity and mortality of these con-
ditions remains poorly deﬁned.
3. Reactive oxygen species contribute to reperfusion injury
The concept that ROS play a role in the injury response to I/R is
Table 1
Clinical conditions associated with ischemia-reperfusion injury.
Single organ involvement
Organ Condition
Central nervous system Stroke
Perinatal hypoxic-ischemic
encephalopathy
Alzheimer's disease
Heart Acute coronary syndrome
Joints Osteoarthritis
Gastrointestinal tract Gastric ulcers
Neonatal necrotizing enterocolitis
Volvulus
Kidney Acute kidney injury
Multiple organ involvement
Condition Manifestations
Hemorrhage & resuscitation Multiple organ failure
Sickle cell disease Acute chest syndrome, priapism
Sleep apnea Oxidative damage, hypertension
Medical or surgical procedure-related
Condition Manifestations
Thrombolytic therapy Stroke, myocardial infarction
Organ transplantation Acute graft failure
Cardiopulmonary bypass Lung injury, heart failure
Coronary angioplasty Heart failure
Arterial tourniquet release Local tissue injury
Thoracoabdominal aortic surgery Spinal cord injury
Compartment syndrome
decompression
Limb edema, muscle injury
Testicular or ovarian torsion/detorsion Infertility
Table 2
Potential sources of reactive oxygen species in tissues exposed to ischemia and
reperfusion.
ROS source Tissue implicated References
Xanthine oxidase Intestine, lung, heart, skin,eye,
brain, skeletal muscle,liver, pan-
creas, stomach, testes,kidney,
joints, spinal cord
[11,475,476,477
478,479,57,
138,480,481,482
483,484,485]
NADPH oxidase Intestine, lung, heart, eyebrain,
stomach, liver, kidneytestes
[214,486,487,207
242,204,488,489
490]
Mitochondria Intestine, lung, heart, brain, skeletal
muscle, liver, kidney, stomach,
testes, spinal cord
[239,491,328,492
493,494,495
496,497,498]
Nitric oxide synthase Liver, heart, (aortic endothelial
cells)
[423,427,429,499]
Cytochrome P450 Lung, heart, kidney [500,501,502]
Lipoxygenase/
cyclooxygenase
Brain,eye, pancreas, stomach [503,478,480,504]
Monoamine oxidase Heart, kidney, brain [352,505,506,507]
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enhance ROS scavenging and/or detoxiﬁcation protect against re-
perfusion injury, (2) artiﬁcial generation of ROS in otherwise
normal tissue recapitulates the injury response to I/R, and (3) de-
tection of enhanced ROS production and their characteristic cel-
lular 'footprints' in post-ischemic tissues. The early ROS scaven-
ging studies employed native superoxide distmutase (SOD) in the
presence or absence of catalase to demonstrate protection against
injury in both in vivo and ex vivo models of I/R [11,56,57]. Ex-
perimental limitations related to the relatively small size and short
circulating half-life of ROS scavenging enzymes led to the devel-
opment and application of polyethylene-glycol(PEG)-conjugated-
forms of both SOD [58] and catalase [59], both of which proved to
be effective in some I/R models. Synthetic, low-molecular weight
SOD mimetics like tempol were also developed to overcome pro-
blems (e.g., antigenicity) associated with the native enzyme that
limited its clinical utility, and these have proven to be effective in
several I/R models [60–63]. Mutant mice that are either deﬁcient
in or overexpress ROS scavenging enzymes, such as SOD, catalase,
and glutathione peroxidase, have also provided results that are
consistent with a role for ROS as mediators of I/R injury in dif-
ferent organs [64–68]. Furthermore, cellular localization of the
source of ROS that contributes to the I/R-induced injury response
has been addressed using mutant mice that overexpress or exhibit
a deﬁciency in one of the three different SOD isoenzymes, i.e., the
cytosolic copper–zinc SOD (CuZn SOD), the mitochondria-asso-
ciated manganese SOD (MnSOD), and extracellular SOD (EC-SOD)
[69,70]. Direct gene transfer of the cDNA encoding SOD has alsobeen shown to afford protection against I/R injury [71]. Native
SOD, PEG-SOD, SOD-mimetics, and genetic overexpression of SOD
or other ROS scavenging enzymes have also been applied, with
considerable success, in different in vitro models of hypoxia (or
anoxia)-reoxygenation [42,69,72–77].
Additional support for the involvement of ROS in I/R injury has
come from studies describing phenotypic responses of cells or
tissues exposed directly to ROS (or a ROS-generating enzyme) that
recapitulate the responses elicited by I/R [19,78]. Hydrogen per-
oxide, a mild and relatively stable oxidant that is generated in
tissues (cells) exposed to I/R (H/R), has been extensively used as a
representative ROS to assess the response of cells to oxidative
stress. At pathophysiologically relevant concentrations (10–
100 μM), H2O2 can elicit most of the phenotypic changes in en-
dothelial function that are evidenced in postischemic (post-
hypoxic) tissues (endothelial cell monolayers) including en-
dothelial barrier dysfunction (increased vascular permeability)
[79], increased expression of endothelial cell adhesion molecules
and enhanced leukocyte–endothelial cell adhesion [80,81], in-
creased production of inﬂammatory mediators (e.g., platelet acti-
vating factor) [81], and the induction of a procoagulant, pro-
thrombotic phenotype [82]. Cardiac myocytes [83] and vascular
smooth muscle [84] also respond to H2O2 in a manner that is
consistent with I/R or H/R, while other cell types (e.g., mast cells)
do not [85]. The molecular basis for the cellular responses elicited
by hydrogen peroxide and the role of this mild oxidant as a sig-
naling second messenger have been extensively characterized [86].
The premise that ROS are generated following I/R was initially
based on the detection of chemical products generated by the
reaction of ROS with cellular lipids, proteins, and other molecules
[10,87,88]. The products of lipid peroxidation (e.g., mal-
ondialdehyde, conjugated dienes, and hydroxynonenol) have been
widely used as ‘footprints’ of ROS generation in different models of
I/R [2,19,34,89]. Oxidation of cellular sulfhydryl groups and the
generation of oxidized glutathione (GSSG) have also been offered
as evidence of oxidative stress and redox imbalance following I/R
in different tissues [90–94]. Oxidant-sensitive ﬂuorochromes (e.g.,
Fig. 3. Potential mechanisms of ROS production by XOR in tissues exposed to
ischemia and reperfusion. In the setting of ischemia, ATP is catabolized to hypox-
anthine and the dehydrogenase form of XOR (XDH) is converted, via limited pro-
teolysis and sulfhydryl oxidation, to the oxidase form (XO). Upon reperfusion, the
restored tissue O2 reacts with hypoxanthine (or xanthine) and XO to generate both
superoxide (O2
−) and hydrogen peroxide (H2O2), which can consequently interact to
yield more reactive secondary species [11,133]. The conversion of XDH to XO may
not be required for ROS production following reperfusion (see boxed area of ﬁgure).
During ischemia, the redox status of the tissue is altered from an oxidative state
(higher level of NADþ relative to NADH) to a reductive state (higher NADH relative
to NADþ). This altered redox state has been shown to enhance the generation of O2−
from XDH in the presence of xanthine [141].
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chloroﬂuorescein (DCF)) have been used to visualize and quantify
ROS production in postischemic tissues and in monolayers of
cultured cells [95–99]. While DCF and DHE exhibit differential
sensitivities to hydrogen peroxide and superoxide, respectively,
electron spin resonance (ESR) spectroscopy and spin trapping has
become the ‘gold standard’ for detection and identiﬁcation of
different ROS produced by tissues and cells in response to I/R
(Fig. 2). This approach, which has been applied to heart [100,101],
kidney [102], skin [103], retina [104], lung [105], intestine [106],
liver [107], and monolayers of cultured cells [108,109], has re-
vealed that the enhanced ROS production elicited by I/R is de-
tected immediately (within 20 s) following reperfusion and that
superoxide (O2
·−) is the parent radical that serves as a precursor for
the hydroxyl radical, carbon-centered radicals and other second-
ary species [2,110]. The more recent application of proteomic and
genomic mapping to tissues (or cells) exposed to I/R (or H/R) is
providing novel insights into the responses of speciﬁc proteins and
genes to the oxidative stress that accompanies this condition [111–
114].
3.1. Sources of ROS in post-ischemic tissue
The oxidative stress elicited in tissues/cells following I/R (or H/
R) has been linked to a variety of different sources of ROS. Non-
enzymatic sources of ROS, such as hemoglobin and myoglobin
(both of which can be released into extracellular ﬂuid after trau-
ma), have received some attention as potential mediators of I/R-
induced oxidative stress [115,116]. However, most studies have
attributed the accelerated ROS production in post-ischemic tissues
to one or more enzymes that are capable of reducing molecular
oxygen to form superoxide and/or hydrogen peroxide, with the
subsequent release of ROS into the intracellular and/or extra-
cellular compartments. Table 2 summarizes the enzymatic sources
of ROS that have been implicated in I/R pathogenesis in different
organs. An examination of the literature reveals that the enzyme
systems most commonly invoked to explain the accelerated ROS
production in postischemic tissues are xanthine oxidase, NADPH
oxidase, the mitochondrial electron transport chain, and un-
coupled nitric oxide synthase. A brief description and assessment
of the involvement of these enzyme systems in reperfusion injury
follows.
3.1.1. Xanthine oxidase
Xanthine oxidoreductase (XOR) is a complex molybdo-
ﬂavoenzyme that controls the rate-limiting step of purine cata-
bolism, i.e., the hydroxylation of xanthine to uric acid. The mam-
malian form of this enzyme exists in two interconvertible forms,
xanthine dehydrogenase (XDH) and xanthine oxidase (XO), with
XDH as the predominant form in normal healthy tissue. XDH
preferably uses NADþ as an electron acceptor, while XO uses O2 as
the terminal electron acceptor thereby exhibiting the ability to
generate ROS. XO has been extensively studied as a potential
source of ROS in tissues and isolated cells exposed I/R or H/R. More
organ systems have been probed for the contribution of this ROS
source than any other potential source (Table 2), which likely re-
ﬂects the fact that safe, inexpensive and effective drugs that inhibit
the enzyme (e.g., allopurinol) have long been available. Despite the
large number of reports describing a beneﬁcial effect of xanthine
oxidase inhibitors in different post-ischemic tissues, there are also
studies that have failed to show protection following XO inhibition
in tissues such as the heart [117], lung [118], and liver [91]. Some of
the inconsistent ﬁndings have been attributed to differences in
XOR abundance/activity between animal species. For example,
rabbit heart, which is not protected against reperfusion injury by
allopurinol treatment, is virtually devoid of XO activity [117], muchlike the human heart [119]. However, intestine and liver, which
exhibit signiﬁcant and ubiquitous expression of XOR across species
(including humans) [120,121], have yielded more consistent ﬁnd-
ings regarding a role for the enzyme in reperfusion injury
[122,123].
While whole tissue homogenates of organs (e.g., heart and
brain) from human and some experimental animals have failed to
exhibit signiﬁcant XOR activity, immunohistochemical studies
have revealed high levels of XOR antigen in vascular endothelium
in these tissues [124,125]. Furthermore, the immunohistochemical
studies have rather consistently demonstrated that the enzyme is
concentrated on the outer surface of the endothelial cell plasma
membrane [124,125]. This observation has lead to the proposal
that the XOR localized on the surface of endothelial cells is derived
from plasma [126]. Animal studies have revealed that circulating
XO levels are signiﬁcantly elevated following exposure of the liver
and/or intestine to I/R [126,127], and that the XO leaking into
plasma can bind to surface glycosaminoglycans (GAG) on vascular
endothelial cells in tissues distant from the liver and/or gut [128].
The GAG-dependent binding of XO to vascular endothelium is
heparin-reversible until the enzyme is endocytosed by the cell
[129,130]. A pathophysiological role for the XO released into
plasma from these enzyme-rich tissues is supported by the ob-
servation that the XO level achieved in plasma is sufﬁcient (with
adequate substrate) to produce severe endothelial cell injury in
vitro [126] and that immunoblockade of the circulating XO has
been shown to protect the lung vasculature from the deleterious
effects of gut I/R [127]. The binding of circulating XO to vascular
endothelial cells has been invoked to explain the effectiveness of
xanthine oxidase inhibitors in blunting the I/R injury response in
tissues that exhibit low XO activity [131]. Nonetheless, there are a
number of reports that demonstrate a role for xanthine oxidase in
the phenotypic changes that occur in cultured vascular endothelial
cells exposed to A/R or H/R [31,42,110] (Fig. 2).
The hypothesis that xanthine oxidase is a major source of ROS
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cular permeability response to reperfusion in cat small intestine,
following a 1 h period of low-ﬂow ischemia [11]. The original
version of this hypothesis (Fig. 3) proposed that the ischemic in-
sult results in depletion of the energy charge of the cell, an ac-
cumulation of hypoxanthine from the catabolism of ATP, and a
concomitant conversion (mediated by limited proteolysis and/or
sulfhydryl oxidation) of the XDH isoform to XO. With the re-
storation of blood ﬂow and tissue oxygen tension at reperfusion, it
was predicted that the readmitted oxygen and accumulated hy-
poxanthine would react with XO to produce a burst of superoxide.
Since allopurinol and superoxide dismutase (SOD) treatments
were equally effective in blunting the I/R-induced vascular per-
meability response, it was concluded that XO-derived superoxide
and/or secondary radical species were largely responsible for the
endothelial barrier dysfunction.
While X-ray crystallography and site-directed mutagenesis
studies have signiﬁcantly improved our understanding of the
changes in enzyme structure and function that occur when XDH is
converted to XO [132], considerable uncertainty remains regarding
the magnitude and kinetics of conversion of XDH to XO that is
elicited by ischemia, and whether this conversion process is a
requirement for XO-dependent ROS production during reperfu-
sion. Initial reports of XDH to XO conversion in rat intestine sug-
gested a very rapid rate of conversion i.e., requiring about 60 s for
complete conversion to the ROS producing XO form [133]. How-
ever, subsequent studies have revealed that XO accounts for 19% of
total enzyme (XDHþXO) activity under control (non-ischemic)
conditions, and that XO activity increases by approximately 13%
per hour of intestinal ischemia [134]. The issue of XDH to XO
conversion during ischemia has been more extensively evaluated
in liver. However, disparate ﬁndings have been reported for this
tissue, with some reports describing signiﬁcant conversion during
ischemia, while others describe little or no conversion following
prolonged ischemia [135,136]. There appears to be a growing
consensus that the conversion of XDH to XO is not a rate-limiting
determinant of ROS production upon reperfusion of ischemic tis-
sue, particularly in liver [123,137]. This contention is supported by
the observation that the hepatocellular injury response to I/R
precedes the conversion of XDH to XO [136,138]. A possible ex-
planation for the enhanced superoxide production in the absence
of XDH to XO conversion during I/R is the observation that XDH
exhibits NADH oxidase activity under acidic conditions (pH 6.5),
wherein XDH oxidizes NADH rather than xanthine [123,139]. In
this regard, it is noteworthy that it has been reported that the
NADH oxidase of XDH has the capacity to generate superoxide at
4-times the rate of XO [139]. However, while allopurinol can in-
hibit the production of superoxide by XO, the drug has no effect on
the NADH oxidase activity of XDH [139,140]. Finally, a recent
analysis of XDH from chicken liver that has the unique property of
being locked in the dehydrogenase form has revealed that XDH
has the capacity to generate large quantities of superoxide (at
approximately half the rate of XO in the presence of xanthine) and
this is regulated by the relative levels of NADþ to NADH, with
more O2
·− produced under reduced conditions when a higher
proportion of the NAD(H) pool is in the reduced state [141]. Since
XDH may remain the dominant form of the enzyme at the time of
reperfusion and the tissue likely remains in a reductive state (low
NADþ to NADH ratio) in the early reperfusion period, XDH may be
a quantitatively more important source of O2
·− than XO during this
period (inset of Fig. 3).
In addition to the post-translational modiﬁcation of XDH
mediated by limited proteolysis and sulfhydryl oxidation, there is
also evidence supporting a role for transcriptional regulation of
the enzyme in response to I/R. Hypoxia and cytokines are two
relevant stimuli that have been linked to increased XDHtranscription. Endothelial and epithelial cells exposed to hypoxia
respond with increases in mRNA and total activity for XO
[142,143], with some studies linking these hypoxia-induced re-
sponses to interleukin-6 mediated activation of the JAK-STAT sig-
naling pathway [143]. XO activity is also regulated by oxygen
tension at the post-translational level, as evidenced by studies
demonstrating an inverse relationship between O2 tension and XO
activity [142,144]. O2 tension-mediated modulation of XO activity
appears to involve enzyme phosphorylation by p38 kinase [145]. A
variety of cytokines, including IL-1, IFN-γ, IL-6 and TNF-α, have
been shown to increase XDH/XO mRNA and to increase total ac-
tivity of the enzyme in different cell populations [146–148]. In-
asmuch as cytokine accumulation, resulting from mast cell de-
granulation and macrophage activation, occurs rapidly following I/
R, these inﬂammatory mediators may exert a signiﬁcant inﬂuence
on XO-mediated ROS production following I/R.
Hypoxanthine and xanthine are two well-characterized pro-
ducts of purine metabolism that accumulate in ischemic tissues. A
recent comparative metabolomic analysis designed to identify the
metabolic signatures in different tissues (liver, kidney, heart, and
brain) subjected to I/R revealed a substantial accumulation of only
three metabolites, hypoxanthine, xanthine, and succinate [149],
conﬁrming the availability of the purine metabolites for XO-
mediated ROS production at reperfusion. However, the need for an
accumulation of hypoxanthine and xanthine in post-ischemic tis-
sue to drive XO-mediated ROS production remains unclear. It has
been estimated that hypoxanthine concentration in the mucosa of
normally perfused healthy intestine is approximately 20 μM and
that bowel ischemia results in an approximate 10-fold increase (to
200 μM) in the concentration of this purine [150]. However, be-
cause the Km of hypoxanthine for XO in the gut is estimated to be
approximately 11 μM [150], it would appear that the concentration
of hypoxanthine in both normal and ischemic gut may not be rate-
limiting for ROS production by XO in this tissue. Comparable or
higher hypoxanthine levels have been reported, both in the pre-
ischemic and ischemic state, in other tissues (e.g., brain) [151],
suggesting that the absence of a critical role for hypoxanthine
accumulation for XO-mediated ROS production at the time of re-
perfusion may not be unique to the intestine. These observations
and conclusions are inconsistent with ﬁndings reported for post-
ischemic heart, in which there are two lines of evidence sup-
porting the view that substrate accumulation initiates and controls
XO-mediated ROS production following I/R. First, it has been
shown that the time-course of ROS production elicited by I/R in
isolated rat hearts is closely correlated with the kinetics of XO
substrate accumulation [152]. Second, pharmacological inhibition
of adenosine metabolism and transport (and the consequent
modulation of tissue xanthine and hypoxanthine levels) has re-
vealed a role for hypoxanthine and xanthine accumulation in de-
termining the severity of the myocardial injury response to I/R
[153]. Furthermore, blockade of xanthine oxidase substrate for-
mation via pharmacologic inhibition of adenosine deaminase
prevents XO-dependent ROS production (measured by electron
paramagnetic resonance spin trapping) and the contractile dys-
function that accompanies reperfusion, while exogenous admin-
istration of hypoxanthine and xanthine reversed the protective
effects of adenosine deaminase inhibition [154]. However, a lim-
itation of the experimental strategy of pharmacological inhibition
of XO substrate accumulation is that it also results in the buildup
of adenosine, which is known to exert a protective effect against I/
R-induced inﬂammation and tissue injury [155,156].
Different treatment strategies have been employed to assess
the contribution of xanthine oxidase to I/R injury, including purine
(allopurinol and oxypurinol) [11,157] and non-purine (febuxostat)
[158] enzyme inhibitors, dietary tungsten supplementation and/or
molybdenum deﬁciency [159,160], and gene deletion [161].
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disorder in humans, generally results in kidney dysfunction and
failure [162]. Similar kidney responses have been reported in both
homozygous and heterozygous XDH knockout mice [161,163].
Consequently, in the absence of tissue-speciﬁc conditional
knockouts for XO, genetic approaches have had little or no impact
to date in deﬁning the role of XO-dependent ROS production in I/R
injury [164]. A large majority of the reports addressing the con-
tribution of XO to reperfusion injury are based on the use of al-
lopurinol or its more water-soluble metabolite, oxypurinol [1].
While allopurinol/oxypurinol treatment has proven to be highly
effective in inhibiting XO activity and ROS production, and in re-
ducing reperfusion injury in several model systems, some con-
cerns have been raised regarding non-speciﬁc actions of the drugs.
For example, it has been proposed that allopurinol and oxypurinol
may offer protection against I/R injury by acting as radical sca-
vengers [165,166]. However, reports describing this action of the
XO inhibitors have employed concentrations that far exceed the
doses needed to inhibit the enzyme. Extracellular ﬂuid (plasma
and lymph) collected from animals receiving the more commonly
used allopurinol/oxypurinol treatment regimens for XO inhibition
does not exhibit an enhanced antioxidant or scavenging potential
[167]. Additional concerns regarding allopurinol/oxypurinol in-
clude the inability of the drugs to block the NADH oxidase activity
of XO [168] and to inhibit XO activity when the enzyme is bound
to GAGs on the endothelial cell surface [169]. The non-purine XO
inhibitor febuxostat appears to overcome some of the limitations
of allopurinol/oxypurinol. The potency of febuxostat is 3-orders of
magnitude greater than allopurinol and it appears to be highly
effective in inhibiting endothelium-associated XO [170]. Febuxo-
stat has been used in a limited number of I/R injury studies of
intestine [171] and kidney [158], showing protection in both stu-
dies. A comparison of allopurinol vs febuxostat effects in a rat
model of local and remote intestinal I/R injury revealed better
protection with febuxostat for some of the indices of inﬂammation
and tissue injury [171].
Much attention has been recently devoted to the ability of XO
to function as a nitrate/nitrite reductase, which enables the en-
zyme to catalyze the one electron reduction of nitrite to nitric
oxide (NO) [123,145,164]. Studies employing puriﬁed enzyme have
revealed the generation of NO from XO in the presence of NO2
−,
with xanthine, NADH, or aldehyde serving as electron donors
[172,173]. Nitrite reduction by XO is enhanced under anoxic/hy-
poxic conditions and by acidosis [174]. Furthermore, NO genera-
tion via this reductive process is inhibited by allopurinol and
oxypurinol [172,173]. The pathophysiological relevance of the NO
generated by XO in conditions such as I/R and inﬂammation re-
mains unclear. However, the capacity of this enzyme to generate
both superoxide and NO has lead to the proposal that XO may be
an important source of peroxynitrite in postischemic and inﬂamed
tissue [175]. Others have proposed that the NO produced during
periods of ischemia may minimize the ROS-mediated damage that
results at the time of reperfusion due to the ability of NO to pro-
mote vasodilation and inhibit inﬂammation [164]. The most con-
vincing evidence supporting a pathophysiological role for the ni-
trite reductase function of XO comes from studies that show
protection against I/R injury following nitrite administration. The
protective effect of nitrite-derived NO in heart [176,177], kidney
[178], lung [179], and liver [180] models of I/R injury are not ob-
served following inhibition of XO with either allopurinol or oxy-
purinol, suggesting that the enzyme plays a critical role in the
generation of NO by NO2
−.
A characteristic response of the vasculature to I/R is an en-
hanced recruitment of inﬂammatory cells, particularly neutrophils
[160,181,182]. Similarly, endothelial cell monolayers exposed to
either H/R or A/R exhibit an increased adhesivity to neutrophils(Fig. 2) [42,43,183]. Xanthine oxidase, more than any other po-
tential source of ROS, has been implicated in the leukocyte re-
cruitment that occurs following I/R in vivo and A/R (or H/R) in
vitro. The substantial neutrophil recruitment (typically measured
as an increased tissue myeloperoxidase activity) observed in tis-
sues exposed to I/R [171,184,185], the enhanced leukocyte–en-
dothelial cell adhesion in post-ischemic venules [43,160,181,182],
and increased neutrophil adhesion to post-hypoxic endothelial cell
monolayers [42,43,183,186] (Fig. 2) are all signiﬁcantly attenuated
by treatment with an XO inhibitor, SOD, or catalase. Studies em-
ploying in vivo and in vitro models have revealed a role for both
inﬂammatory mediator production/release [42,43,183,187,188]
and increased expression of endothelial cell and leukocyte adhe-
sion molecules [42, 43, 160] as potential links between XO-de-
pendent ROS production and the leukocyte recruitment response
to I/R. Hydrogen peroxide, which is known to initiate the pro-
duction of platelet activating factor (PAF) and increased surface
expression of P-selectin [81,189], appears to play an important role
in this regard. Endothelial cell monolayers exposed to A/R exhibit a
biphasic neutrophil adhesion response [42], with an early (30 min)
enhancement of adhesion that is transcription-independent and
inhibited by treatment with either oxypurinol, catalase and
blocking antibodies for either P-selectin or ICAM-1 (Fig. 2). At
240 min following reoxygenation, a second phase of neutrophil
hyperadhesivity is noted that is transcription-dependent and in-
hibited by treatment with either a PAF receptor antagonist, E-se-
lectin blocking antibody, or antisense oligonucleotide directed
against the oxidant-sensitive transcription factors, nuclear factor
kappa-B (NFkB) or activator protein-1 (AP-1) [42]. In vivo studies
have conﬁrmed a role for PAF, ICAM-1 and P-selectin as mediators
of XO-dependent leukocyte recruitment in postischemic venules
[160,187,188]. Based on these observations it has been proposed
that XO-derived ROS may play a more important role in mediating
the reperfusion injury response by promoting the recruitment
and/or activation of leukocytes, rather than XO-derived ROS di-
rectly mediating the tissue injury response [19,190–193]. This
possibility is supported by reports describing a comparable level of
protection against I/R injury following either inhibition of xan-
thine oxidase, induction of neutropenia, or blockade of leukocyte-
endothelial cell adhesion [19,160,194–197]
3.1.2. NADPH oxidase
The Nox/Duox family of NADPH oxidases has also been im-
plicated in the production of ROS following I/R [198–202]. This
family of multiprotein complexes is comprised of 7 members,
designated as Nox-1 to Nox-5 and as dual oxidases (Duox)-1 and
-2 [202]. The Duox enzymes predominately produce hydrogen
peroxide along with Nox-4, while the remaining Nox isoenzymes
largely produce superoxide [199]. Although the NADPH oxidases
are ubiquitously expressed, cell-speciﬁc localization of some iso-
enzymes (e.g., Nox-3 in inner ear, Nox-5 in spleen and testes) has
been described. Nox-2 (formerly known as gp91phox) accounts for
the ability of phagocytic cells (neutrophils) to generate ROS, but
the enzyme is also present in all cells comprising the walls of
blood vessels. Generally, the non-phagocytic Nox isoenzymes are
expressed at lower levels than Nox-2 in phagocytes. Nonetheless,
signiﬁcant mRNA and protein levels for Nox/Duox are detected in
many tissues and these enzymes are proving to be a major source
of ROS in a variety of pathological conditions, including I/R [200–
202]. A role for NADPH oxidase as a mediator of I/R injury has been
proposed for a variety of tissues (Table 2). The proposition that
Nox enzymes contribute to reperfusion injury is largely based on
two lines of evidence, i.e., (1) an increased expression and/or ac-
tivity of Nox in postischemic tissue [203–209], and (2) an at-
tenuation of the I/R- (or H/R-) induced injury response and/or
reduced ROS production following pharmacologic inhibition [204–
Fig. 4. Evidence implicating leukocyte-associated Nox in the lung injury response to 1 h ischemia and 2 h reperfusion. Data are presented for postischemic lungs from bone
marrow chimeras produced by the transplantation of marrow from wild type (WT) mice into p47phox/ recipients or vice versa (donor-recipient). (Panel A) Mal-
ondialdehyde (MDA) level in bronchioalveolar lavage ﬂuid after reperfusion. (Panel B) Lung vascular permeability estimated from Evans blue accumulation in lung tissue.
(Panel C) Pulmonary edema measured by wet/dry weight ratio after reperfusion. (Panel D) Lung airway resistance after reperfusion. Data derived from Yang et al. [216].
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[207,210,215–219]
Studies implicating neutrophils in reperfusion injury provided
some of the earliest evidence suggesting the involvement of Nox as
a source of ROS in postischemic tissue [194,220–224]. Neutrophil-
dependent reperfusion injury has been implicated in a variety of
tissues including heart [220], kidney [225], intestine [194], stomach
[223], lung [197], skeletal muscle [196], brain [226], liver [227], skin
[228], testes [229], as well as the systemic, multiple organ damage
resulting from hemorrhagic shock [230], and the lung injury that
accompanies reperfusion of intestine [231]. The potential involve-
ment of neutrophils is supported by the observation that the time-
course of the inﬂammatory cell accumulation corresponds with
increased ROS generation and/or tissue injury following reperfusion
[160,232]. However, more convincing evidence has been provided
by studies that show attenuated tissue injury and/or ROS produc-
tion when reperfusion-induced neutrophil accumulation is blunted
by either rendering the animal neutropenic [194,220,233], blocking
neutrophil adhesion to vascular endothelial cells [194,234,235], or
by blocking the production of (or receptors for) mediators (e.g.,
platelet activating factor, and leukotriene B4) that are engaged in
the recruitment of leukocytes [188,236–238]. Since inhibitors of
ROS production or ROS scavengers have also been shown to be si-
milarly effective in blunting reperfusion injury in these experi-
mental models, it is generally assumed that the neutrophils are a
major source of the ROS that mediate this response. However a
reasonable alternative conclusion is that ROS generated from an-
other cellular/enzymatic source (e.g., xanthine oxidase or mi-
tochondria) play an essential role in the recruitment and activation
of neutrophils [160,184,239], which ultimately mediate the tissue
injury via a ROS-independent mechanism, such as proteases [240]
or physical obstruction of the microvasculature [241]. The most
convincing evidence supporting a role for neutrophil-associated
Nox in reperfusion injury comes from studies employing bonemarrow (BM) chimeras created by transplanting bone marrow from
NADPH oxidase (Nox-2) deﬁcient mice into wild type (WT) re-
cipients. Studies of brain I/R have revealed either a partial [242] or
dominant [243] role for BM-derived cells (likely leukocytes) in
mediating the NADPH oxidase dependent blood brain barrier dys-
function and brain infarction following ischemic stroke. Reperfusion
injury (increased vascular permeability, edema, oxidative stress, and
increased airway resistance) in the lung is also attenuated in
p47phox-deﬁcient mice. Furthermore, a comparison of the responses
between WT-WT, p47phox /-WT, and WT-p47phox / chi-
meras suggests that leukocyte-associated Nox has a dominant role
in mediating lung injury following I/R [216] (Fig. 4).
There are several lines of evidence that support a role for non-
phagocytic Nox as a source of ROS following I/R (or H/R). It has
been demonstrated that puriﬁed cultured cell populations, in-
cluding endothelial cells [244], cardiac myocytes [245] and neu-
rons [246] exposed to simulated I/R in vitro exhibit tissue injury-
related responses that are dependent on Nox activity. For example,
endothelial cells exposed to H/R show increases in NADPH oxidase
expression/activity, superoxide production, NFkB activation, E-se-
lectin expression, and adhesivity to leukocytes, with a corre-
sponding reduction in barrier function. All of these responses are
largely prevented by treatment of the endothelial cells with the
Nox inhibitors, apocynin or diphenyliodonium (DPI), or with in-
hibitors of the signaling pathways that regulate Nox activation
[244,247–250]. It has also been reported that the generation of
ROS in hippocampal and cortical neurons in culture is signiﬁcantly
increased after oxygen/glucose deprivation and reoxygenation, but
this response is absent following treatment with either apocynin
or DPI and in cells derived from gp91phox knockout mice [246].
Similarly, cardiac myocytes subjected to in vitro simulated I/R
display increased ROS production, enhanced lipid peroxidation,
activation of redox-sensitive kinases (ERK, JNK) and cell death, all
of which are prevented by DPI treatment [245]. Isolated buffer
Fig. 5. Stimuli that may act on Nox-2 positive cells following ischemia and reperfusion to elicit activation and/or induction of the enzyme. Hypoxia-inducible factor-1α (HIF-
1α), leukotriene B4 (LTB4), platelet activating factor (PAF), complement component-5a (C5a), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interferon-Υ (IFN-γ).
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intravascular Nox-positive cells such as PMNs, have also revealed a
role for NADPH oxidase in the injury response to H/R. For example,
isolated buffer perfused rat and mouse lungs exhibit enhanced
ROS production following H/R and this response is blocked by
treatment with either DPI or the synthetic peptide inhibitor of
Nox, PR-39, with a similar attenuation of ROS production noted in
isolated lungs derived from gp91phox knockout mice [251]. Other
reports have similarly described a protective effect of Nox in-
hibitors in isolated buffer (cell free) perfused hearts exposed to H/
R [252] and in buffer-perfused Langendorff preparations with
hearts derived from mutant mice deﬁcient in either Nox-1 or Nox-
2 [253]. A third line of evidence that implicates non-phagocytic
cell-associated Nox in I/R injury comes from studies of mice that
are deﬁcient in Nox isoforms not expressed in phagocytic cells. For
example, Nox-4, which is expressed in astrocytes, neurons and
microglia in the brain (but not in PMNs) [202], exhibits an in-
creased expression following ischemic stroke [254,255]. Mice de-
ﬁcient in Nox-4 are protected against stroke, with reductions in
infarct size, oxidative stress, neuronal apoptosis, and BBB leakage,
compared to their WT counterparts [256]. Studies of myocardial I/
R injury in Nox-isoform speciﬁc knockout mice have revealed that
Nox-1, Nox-2 and Nox-1/Nox-2 double knockouts have sig-
niﬁcantly reduced infarct sizes, compared to WT controls, while
Nox-4 deﬁcient mice show no protection. Since hearts from Nox-1
and Nox-2 knockout mice were similarly protected against I/R
injury in the buffer perfused Langendorff model, it was concluded
that the beneﬁcial effects of these Nox isoform deletions are in-
trinsic to heart tissue, i.e., myocytes [253].
With the exception of Nox-4, all of the Nox homologs are
constitutively inactive and require cell stimulation to generate
ROS. In the resting state, critical protein subunits (e.g., p47phox,
p40phox, and p67phox), and the small GTPase Rac1/2 of the enzyme
are partitioned in the cytosol and spatially segregated from large
catalytic core subunits (e.g., Nox-1 and Nox-2) that are integrated
in the cell membrane (Fig. 5). Upon cell activation, the regulatory
cytosolic subunits are assembled and translocated to the cell
membrane where they dock with the Nox homolog. The fully as-
sembled enzyme then generates superoxide via one-electron re-
duction of molecular oxygen using cytoplasmic NADPH as an
electron donor [200,202,257]. While the signaling mechanisms
that regulate NADPH oxidase assembly and activation are not
completely understood, there is considerable evidence to support
the potential involvement of a variety of factors in the activation of
NADPH oxidase in tissues exposed to I/R. For example, the hypoxia
that accompanies ischemia elicits the production and release of
hypoxia inhibitory factor-1α (HIF-1α), which in turn promotes the
production and activation of Nox [244,258]. This activation me-
chanism is reinforced by the existence of a positive feedback loopwherein Nox-derived ROS stimulates the production of HIF-1α
[201,259]. Similarly, it has been demonstrated that the reduction
in shear stress that occurs during ischemia, results in endothelial
cell membrane depolarization via inactivation of ATP-sensitive
potassium channels, which leads to activation of NADPH oxidase
[260].
During ischemia and at the time of reperfusion, different che-
mical mediators with the potential to activate NADPH oxidase are
produced and released by cells. The activation of phospholipase A2
that accompanies I/R results in the production of platelet activat-
ing factor (PAF) as well as the generation of arachidonic acid and
its subsequent metabolism to thromboxane and leukotrienes (e.g.,
LTB4), all of which engage with speciﬁc cell receptors and ulti-
mately prime or activate NADPH oxidase [1,261–263]. Another
consequence of I/R is activation of the complement system, which
has also been implicated in the increased activity of NADPH oxi-
dase in post-ischemic tissue [203,264]. Various cytokines (e.g.,
TNF-α, IL-1β) that are liberated from macrophages and mast cells
following reperfusion have been shown to elicit both an increased
activity and expression of NADPH oxidase [265–267], with cyto-
kine blockade resulting in an attenuation of reperfusion-induced,
NADPH oxidase-dependent ROS production [268]. Finally, angio-
tensin II, perhaps the most studied and best characterized stimu-
lant for NADPH oxidase activation [269], has been implicated in
reperfusion-induced NADPH oxidase activation, inﬂammation, and
injury in several tissues [270–274]. These effects are mediated via
engagement of the angiotensin II-type-1 receptor and likely in-
volve the local generation of angiotensin II via angiotensin con-
verting enzyme and chymase during I/R. Collectively, the available
data in the literature suggest that I/R leads to the production of a
diverse group of chemical mediators with a shared capacity to
enhance both the activity and expression of Nox (Fig. 5), enabling
the enzyme to generate ROS and mediate reperfusion injury.
Much of the evidence supporting a role for NADPH oxidase in
reperfusion injury has come from studies employing the phar-
macological inhibitors, apocynin and DPI. Apocynin exerts its in-
hibitory effect on Nox by interfering with membrane translocation
of p47phox and p67phox, while DPI, a ﬂavoprotein inhibitor, alters
the electron transport capacity of the enzyme [200,201,275, 276].
Although both agents can effectively inhibit NADPH oxidase ac-
tivity, they also exert other actions on cells that can make it dif-
ﬁcult to attribute the actions speciﬁcally to Nox inhibition. For
example, apocynin can act as an antioxidant, inhibit Rho kinase,
and alter nitric oxide synthesis as well as arachidonic acid meta-
bolism, while DPI inhibits a variety of ﬂavoenzymes, including
xanthine oxidase, nitric oxide synthase, and cytochrome P450
reductase, and inhibits mitochondrial enzymes [275–279]. The
peptide inhibitors (e.g., PR-39 and gp91ds-tat) appear to offer
greater speciﬁcity and some degree of selectivity to speciﬁc Nox
Fig. 6. ROS production by the electron transport chain (ETC): role of mitochondrial proton motive force (Δψ). Electron carriers, NADH and FADH2 feed electrons (e) into
complex I and complex II of the ETC, respectively. As e traverse through the ETC they release some of their energy to pump Hþ into the intermembrane space generating a
Δψ. The Δψ is used to move Hþ through ATP synthase and phosphorylate ADP to ATP. At several points along the ETC (esp. complex I and III) there is a potential for e to leak
and reduce O2 to superoxide (O2
·−). The rate of O2
·− production is directly related to the level of Δψ; Δψ was varied using an uncoupling agent or inhibitors of ETC (inset; from
Korshunov et al. [318]). A feedback mechanism exists to limit O2
·− production by dissipating the Δψ. In this scenario, excessive O2
·− production activates the uncoupling protein
(UCP) allowing Hþ to diffuse back into the matrix bypassing the ATP synthase. The increased efﬂux of Hþ lowers the Δψ and reduces O2
·− production. Red arrows, forward e
ﬂow; red dashed arrow, reverse electron ﬂow; Q, Coenzyme Q; Cyt, cytochrome c. (modiﬁed from Krauss et al. [326] and Chen and Zweier [298]).
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growing interest in developing small molecule Nox inhibitors with
greater speciﬁcity and isoform selectivity that can be used in hu-
man trials of ischemic disease [200,201,280,281].
3.1.3. Mitochondria
Estimates of ROS production by mitochondria vary con-
siderably, both quantitatively and qualitatively [282]. Some of this
variability can be attributed to the lack of speciﬁcity and sensitivity
of approaches used to measure the short lived ROS, particularly
in vivo [283–285]. In addition, there are signiﬁcant differences
among species, tissues, cells, and even intracellular pools from
which the mitochondria are derived [9,286,287]. Various isolation
procedures may also impact mitochondrial structure and function
[288,289]. Finally, the speciﬁc experimental conditions imposed
(e.g., inhibitors of electron transport and uncoupling agents) can
result in abnormal mitochondrial function [290]. Given these ca-
veats, it can be argued that the use of isolated mitochondria, sub-
mitochondrial particles, or puriﬁed mitochondrial components
(e.g., electron transport chain or TCA cycle enzymes) may have
very little bearing on mitochondrial function in a normal cellular
and/or tissue milieu [290–292]. However, reductionist approaches
have proven useful for dissecting the various cellular/molecular
mechanisms involved in mitochondrial function. Examples of the
utility of these approaches include the TCA cycle and the che-
miosmotic mechanism of oxidative phosphorylation [288]. Simi-
larly, these approaches have greatly fueled progress in under-
standing the mechanisms by which mitochondria generate ROS.
Speciﬁc intra-mitochondrial sites of ROS production and their
targets have been identiﬁed [293], and signiﬁcant advancements
have been made in our understanding of the contributions of
mitochondria-derived ROS to both redox signaling [294–297] andI/R-induced pathology [9,295,296,298–300].
Mitochondria have been implicated as a major source of I/R-
induced ROS production in a variety of organs (Table 2); especially
in those that are highly metabolically active, i.e., heart and brain
[9,290,296,298,301]. This is not entirely surprising given the gen-
eral view that mitochondria most likely generate ROS during the
course of normal oxidative phosphorylation. The rapid movement
of electrons through the electron transport chain (ETC) of the in-
ner mitochondrial membrane can result in the leakage of electrons
that can form O2
·− via univalent reduction of O2 [282,290,295,302–
308]. Mitochondria contain enzymes that can generate ROS both in
the matrix (e.g., TCA cycle) and in the membrane (e.g., NADPH
oxidase) [290,296,309]. Herein, we discuss the general character-
istics of the various mitochondrial sources of ROS and their po-
tential roles in I/R.
Mitochondria synthesize most of the cell's ATP by oxidative
phosphorylation. Catabolism of carbohydrates (glycolysis), lipids
(β-oxidation of fatty acids), and proteins (glucogenic and ketogenic
pathways) yields products that enter the TCA cycle in the mi-
tochondrial matrix. Intermediates generated during the oxidation
reactions of the TCA cycle donate their reducing equivalents (Hþ
and electrons) to NADþ and FADH to generate NADH and FADH2.
β-oxidation of fatty acids in the mitochondrial matrix also con-
tributes to the matrix pool of NADH and FADH2. Matrix NADH and
FADH2 feed electrons and Hþ into the ETC (Fig. 6). The ETC is
comprised of a series of multi-subunit complexes (complexes I–IV)
in the inner mitochondrial membrane that are coupled to mobile
carriers (coenzyme Q and cytochrome c). The complexes and
mobile carriers contain redox groups (Fe-S clusters and/or heme)
that allow for the transfer of electrons along the components of
the ETC [9,290,308]. They receive and transfer electrons in a se-
quence based on increasing redox potential (afﬁnity for electrons)
Fig. 7. Mitochondrial anti-oxidant system. Superoxide (O2
·−) generated by the ETC (see Fig. 6 ) is converted to H2O2 by superoxide dismutase (SOD); MnSOD in the matrix and
CuZnSOD in the intermembrane space, respectively. Catalase, glutathione peroxidase (GPx), and peroxiredoxin (Prx) convert H2O2 to H2O. GPx and Prx require glutathione
(GSH) and thioredoxin (TrxSH) for their reduction, respectively. Glutathione disulﬁde (GSSG) is reduced back to GSH by glutathione reductase (GR), while TrxS is reduced
back to TrxSH by thioredoxin reductase (TrxR). Both GR and TrxR depend on reducing equivalents from NADPH generated by transhydrogenase (NNT) (modiﬁed from
Murphy [308] and Kowaltowski et al. [304]).
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while FADH2 to complex II; electrons from these complexes are
subsequently shuttled through complex III and IV. The energy
released as electrons move through the ETC is used to transport
Hþ from the mitochondrial matrix to the inner membrane space.
Since the inner mitochondrial membrane is impermeable to Hþ , a
proton electrochemical gradient develops across the inner mem-
brane with the inner membrane space more positive (and acidic)
relative to the matrix. This proton-motive force is attributed pri-
marily to the membrane potential (Δψ) with a minor contribution
by the pH gradient (ΔpH). The proton-motive force is used to
transport Hþ through the membrane spanning complex, ATP
synthase, thereby providing the energy for phosphorylation of
ADP to form ATP.
Some of the mitochondrial complexes are organized into “su-
percomplexes” or “respirosomes”, rather than existing as in-
dependent complexes within the inner membrane. For example,
complexes I, III, and IV exist both as free individual components
and as supercomplexes containing various proportions of two (e.g.,
I–III) or three complexes (I–III–IV) [295,310–312]. Supercomplex
assembly and integrity is dependent on cardiolipin, a phospholipid
present in the mitochondrial inner membrane [313,314]. It is
generally, albeit not universally [315], held that supercomplexes
provide structural/functional linkages between the individual
complexes thereby facilitating the tight coupling of electron
transfer, with little or no leak of electrons [295,310–312]. Thus,
during normal metabolic activity most, if not all, of the electrons
entering the ETC converge on cytochrome c oxidase (complex IV)
where they reduce O2 to H2O. Interestingly, it has been proposedthat oxidative damage to cardiolipin during I/R can result in dis-
assembly of complex I and III from the supercomplex, thereby
increasing the probability of ROS generation [295,312].
All of the components of the ETC have redox potentials that
render them capable of transferring single electrons to O2 to form
O2
·− [295,308]. Thus, the mitochondrial ETC is considered to be the
major source of ROS during normal oxidative metabolism
[9,290,296,298,308]. If mitochondria are respiring normally and
generating ATP, H2O2 efﬂux from these organelles is minimal (0.1–
0.2% of O2 consumed) [286,295,308,316,317]. Furthermore, as mi-
tochondrial respiration rate increases, ROS production tends to
decrease [286,318]. Presumably, the low level of detectible ROS is
due to the presence of an extensive intra-mitochondrial anti-
oxidant system [282,304] (Fig. 7). In order for mitochondrial ROS
production to increase sufﬁciently to overcome the endogenous
antioxidant system and achieve detectable levels, signiﬁcant
changes must occur, including exhaustion of the antioxidant sys-
tems, substrate modulation, and/or inhibition of ETC complexes
[286,318].
Substrate modulation or inhibition of individual mitochondrial
complexes is commonly used to identify the speciﬁc complexes that
are responsible for ROS production by the ETC. For example, under
normal conditions, mitochondria from the heart, brain, or kidney
produce larger amounts of H2O2 in the presence of succinate (tar-
geting complex II), when compared to α-ketoglutarate (targeting
complex I) [286]. Pharmacologic blockade of a distal complex re-
sults in the reduction of the proximal complexes (e.g., backup of
electrons). The more reduced the proximal complexes become, the
more likely these complexes will leak electrons and generate O2
·−
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·− pro-
duction appear to be complexes I and III [282,290,304–
306,308,319]. Complex I releases O2
·− into the matrix, while complex
III releases O2
·− into both the matrix and the intermembrane space.
Complex II which is a component of both the ETC and TCA cycle
(succinate dehydrogenase) is generally dismissed as a major source
of ROS, since excessive substrate (succinate) has to be supplied for
complex II to generate O2
·− [290]. However, it must be noted that
others consider complex II as a reasonable source of electron leak,
since the succinate concentrations used are within limits achieved
in the heart and brain, particularly during ischemia [149,305,320].
In addition, complex II may be an indirect source of electron leak via
complex I by reverse electron transport (RET). RET is an energy
requiring process by which electrons entering complex II (via suc-
cinate oxidation), reach coenzyme Q (CoQ) and, instead of pro-
ceeding forward to complex III, are directed back to complex I
[307,308] (Fig. 6). Complex IV (cytochrome c oxidase) tends to
tightly sequester electrons for the complete reduction of O2 to H2O,
and thus is not believed to be a physiologic source of electron leak
[321]. However, there is evidence that phosphorylation of complex
IV can alter its function such that it may generate O2
·−, particularly
during hypoxia [322]. In summary, all the complexes have the redox
components needed to generate ROS, but the general consensus
holds that complexes I and III are the major potential sources under
normal conditions [282,290,291,306,308].
O2
·− production by complexes I and III appears to be directly related
to the membrane potential (Δψ) and/or the redox state of NADH/
NADþ . Speciﬁcally, superoxide production by complex I is optimized by
a high matrix NADH/NADþ ratio (e.g., ischemia) and/or a high Δψ (e.g.,
non-phosphorylating conditions) both of which favor reduction of
electron carriers [282,305,307,308]. A high NADH/NADþ ratio favors
excessive movement of electrons through complex I and, if down-
stream electron carriers are reduced, the likelihood of superoxide
production increases. Another mechanism by which complex I gen-
erates O2
·− is by RET via complex II; usually requiring succinate as a
substrate [305,308]. RET is facilitated by a reduced CoQ and a high Δψ.
The high membrane potential provides the required energy to drive
electrons in reverse from CoQ to complex I (RET). This process has been
noted to produce a substantial amount of O2
·− in brain, heart, muscle
and liver mitochondria [308]. The Q-cycle mechanism, which involves
oxidation/reduction cycles of quinone, accounts for superoxide gen-
eration by complex III. This redox cycling of quinones generates un-
stable semiquinone intermediates at the cytoplasmic and matrix as-
pects of the inner mitochondrial membrane [282,290,291,295,298].
These semiquinones are believed to be the sources of O2
·− generation,
particularly during conditions associated with an increase in Δψ
[295,298]. The superoxide generated at complex III is directed to either
the matrix or intermembrane space; with the latter target likely fa-
vored [282,298].
The direct relationship between mitochondrial Δψ and ROS
production [283,318] provides the basis for the notion that un-
coupling of oxidative phosphorylation blunts mitochondrial O2
·−
production (Fig. 6) [290,308]. Mitochondrial uncoupling involves
an increase in permeability of the inner membrane to Hþ , thereby
dissipating the Hþ gradient necessary for ATP synthesis. Indeed,
mitochondrial uncoupling proteins (UCPs) are believed to function
as regulators of mitochondrial ROS production [323]. In this sce-
nario, excessive mitochondrial ROS production leads to an increase
in UCP, which promotes protein leak back into the matrix; thereby
reducing the Δψ (Fig. 6) [324–326]. A strategy of “mild” un-
coupling is envisioned that reduces ROS production without
compromising mitochondrial ATP production. Although un-
coupling has been proposed as an endogenous protective me-
chanism in both mitochondrial physiology and pathology [323], it
appears to be dysfunctional in I/R. For example, while uncoupling
does reduce ROS production under basal conditions, uncouplinghas no effect on ROS production by mitochondria isolated from I/
R-challenged hearts [327].
It is fairly well established that I/R can alter mitochondrial
structure and function. Mitochondria from I/R-challenged hearts
exhibit deranged cristae, decreased number of supercomplexes
and compromised ETC activity during the ischemic period. These
ultrastructural and functional defects partially recover upon re-
perfusion, and are accompanied by increased O2
·− generation
[287,292,328–332]. It has been proposed that ischemic damage to
complex I and III enhances their capacity to generate O2
·−, setting
the stage for a burst of ROS production upon reperfusion [331].
Isolated supercomplex I–III from mitochondria obtained from re-
perfused hearts can generate O2
·− [328]. When the two individual
complexes are separated from the supercomplex, both complex I
and complex III still generate O2
·− [328,329]. It has been proposed
that upon reperfusion, partial recovery of ETC activity without
supercomplex re-assembly results in impaired oxidative phos-
phorylation and enhanced O2
·− production [329,330]. Moreover, the
enhanced production of ROS by ETC complexes may in turn da-
mage adjacent complexes, propagating ETC dysfunction and am-
plifying ROS production [292].
All of the ETC complexes have been implicated as both sources
and targets of the ROS generated during I/R [287,298,321,333,334].
Consequently, considerable effort has been devoted to deﬁning the
mechanism(s) by which ETC complexes are targeted by ROS and
can act as initiators of mitochondrial ROS production. Oxidant
challenge of submitochondrial particles (membranes containing
ETC complexes) inactivates various complexes; with hydroxyl ra-
dical being more potent than O2
·− or H2O2 [335]. Other redox-
sensitive mechanisms have also been implicated in I/R-induced
ROS production by mitochondrial ETC, and there is evidence fa-
voring a role for ROS-induced peroxidation of cardiolipin and/or
alterations in the phosphorylation status of the complexes. Car-
diolipin, a phospholipid of the inner mitochondrial membrane, is
critical for normal activity of the ETC complexes [313,314]. I/R-
induced decreases in the activities of complexes I and III are as-
sociated with cardiolipin peroxidation [328,330,336,337]. Liposo-
mal delivery of exogenous intact cardiolipin, but not oxidized
cardiolipin, can restore complex I and III activities. Cardiolipin is
also important for stabilization of complex IV and oxidation of
cardiolipin will lead to disassembly of complex IV, thereby de-
creasing its activity [321]. Collectively, these observations support
the contention that cardiolipin is critical for complex assembly,
stability, and appropriate electron transfer. I/R-induced oxidative
stress results in peroxidation of cardiolipin, rendering it ineffective
in stabilizing the complexes, and upon disassembly the complexes
generate additional ROS causing progressive mitochondrial dys-
function [295,321,337,338].
All of the ETC complexes (complexes I–V) contain potential
sites for phosphorylation (e.g., serine, threonine residues), and it
has been proposed that either translocated or resident kinases/
phosphatases can regulate their phosphorylation status [339]. For
example, the redox-sensitive δPKC translocates to the mitochon-
dria after reperfusion of the ischemic myocardium where it in-
itiates O2
·− production [340]. Moreover, in mitochondria isolated
from (1) hearts challenged with I/R or (2) cells grown under hy-
poxic conditions, complex IV (cytochrome c oxidase) is phos-
phorylated [322]. In both situations complex IV activity is com-
promised and there is an increase in O2
·− production. The I/R-in-
duced complex IV hyper-phosphorylation and inactivation, en-
hanced ROS production, and myocardial injury are mitigated by
pharmacologic inhibition of protein kinase A [322,341]. Of note,
the hypoxia-induced increase in mitochondrial PKA activity has
been attributed to local generation of ROS [342]. Based on the
available data, it has been proposed that during ischemia the ETC
complexes are de-phosphorylated (at least complex IV) by
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plexes generate excessive ROS [9].
ETC complexes may also serve as the initial generators of ROS
in postischemic tissue. As mentioned above, the activities of the
ETC complexes are diminished during ischemia and then recover
upon reperfusion [329]. When the reactivation of complex I is
delayed, the reperfusion-induced generation of H2O2 is prevented
and myocardial infarct size is reduced [343]. Additional support for
a primary role for ETC complexes in initiating mitochondrial ROS
production stems from a metabolomic analysis of various tissues
subjected to ischemia [149]. A common metabolite that was in-
creased in ischemic heart, brain, kidney, and liver was the TCA
cycle intermediate, succinate. The increase in succinate accumu-
lation was attributed to a reversal of succinate dehydrogenase
activity by a switch to anaerobic metabolism during ischemia.
Prevention of succinate accumulation during the ischemic period
abolished mitochondrial H2O2 production upon reperfusion and
ameliorated the injury in heart and brain. Moreover, pharmaco-
logic inhibition of complex I has led to the proposal that the oxi-
dation of succinate by complex II upon reperfusion results in RET
through complex I and ROS generation [149]. Interesingly, succi-
nate accumulation in the neonatal brain after ischemia/hypoxia (I/
H) appears to be beneﬁcial in limiting infarct size [344]. Unilateral
common carotid artery occlusion followed by systemic hypoxia
(no reperfusion) resulted in transiently increased succinate con-
centrations in the penumbral region within 90 min and sig-
niﬁcantly reduced infarct size at 4 days post-I/H. The protective
effect of succinate was attributed to the ability of this metabolite
to induce angiogenesis. Collectively, these observations indicate
that the increase in succinate levels during ischemia results in
enhanced mitochondrial ROS production and more tissue injury
upon reperfusion, yet in the absence of reperfusion succinate ap-
pears to prevent expansion of ischemic injury by restoring the
energy status in the affected region via angiogenesis.
There are a variety of other mitochondrial sources of ROS that
may also contribute to the accelerated ROS production associated
with I/R. For example, Nox4 has been implicated as a source of
mitochondrial ROS generation [290,296], presumably due to its
localization in mitochondria [345,346]. However, Nox4 has also
been localized to the plasma membrane as well as ER and mi-
crosomal membranes [346,347]. As addressed above, the role of
Nox-4 in I/R-induced tissue injury is controversial, with some
studies demonstrating protection [256] and others showing no
protection [253] against the injury response in Nox-4 deﬁcient
mice. Despite the absence of a consensus regarding the role of
Nox-4 in I/R-induced oxidant stress and tissue injury, the multiple
loci of Nox-4 makes it difﬁcult to ascribe a speciﬁc role for mi-
tochondria-associated Nox-4 as a mediator of this response.
Monoamine oxidase (MAO), localized on the outer mitochon-
drial membrane, is known to generate H2O2 as an obligatory by-
product of oxidative deamination of neurotransmitters and other
biogenic amines [290,295,296,348]. As expected, MAO is prevalent
in brain neurons; but it is also expressed in peripheral tissues (e.g.,
heart, kidney, liver, and intestine). There are two isoforms with
different substrate speciﬁcities; MAO-A (e.g., norepinephrine and
dopamine) and MAO-B (e.g., serotonin and histamine). Over-
expression of cardiac MAO or dopamine administration can trigger
H2O2 production by cardiomyocyte mitochondria [285,349], while
knockdown of MAO-A (microRNA) reduces neuroblastoma cell
ROS production by 50% [350]. Of particular relevance are the ob-
servations that pharmacologic blockade of MAO can ameliorate I/
R-induced injury to the heart [351,352] and brain [353,354].
The p66Shc protein is an isoform of the adaptor protein ShcA
that can be activated by ROS (among other apoptotic stimuli) and,
in turn, generate ROS [290,295]. There appear to be cytoplasmic,
ER, and mitochondrial pools of inactive p66Shc [355,356]. Inresponse to oxidative stress signals, there is an increase in the
mitochondrial pool of p66Shc [356] where it interacts with cyto-
chrome c of the ETC [355]. Active p66Shc diverts electrons from the
ETC by oxidizing cytochrome c and reducing O2 to O2
·−/H2O2
[355,356]. In addition to generating ROS, it can also inhibit tran-
scriptional upregulation of antioxidant enzymes [357]. Genetic
ablation of p66Shc decreases oxidant stress in various cells and
tissues [358–360]. Furthermore, mice deﬁcient in p66Shc exhibit
less I/R injury in heart [359] or skeletal muscle [358].
The structurally related pyruvate dehydrogenase (PDH) and α-
ketoglutarate dehydrogenase (α-KDH) complexes, as well as other
NAD-linked dehydrogenases, are capable of producing O2
·−/H2O2
under appropriate experimental conditions (e.g., high substrate
and increased NADH/NADþ ratio) [361–363]. The ROS generating
capabilities of PDH and α-KDH are attributed to the dihy-
drolipoamide dehydrogenase subunit, common to both [364].
Under optimum conditions, the maximum achievable rates of ROS
generation by PDH and α-KDH into the matrix can exceed that of
complex I [361]. α-glycerophosphate dehydrogenase (α-GPD) is
another NAD-linked dehydrogenase that is localized to the outer
surface of the inner membrane and capable of generating ROS
primarily into the intermembrane space [317,362]. It has been
proposed that the NAD-linked dehydrogenases may make a sig-
niﬁcant contribution to mitochondrial ROS production in post-
ischemic tissue, since the mitochondrial NADH/NADþ ratio is
elevated in response to ischemia/hypoxia [362]. However, the only
experimental evidence that supports this contention is the ob-
servation that pharmacologic inhibition of α-KDH can protect
against hypoxia- or H2O2-induced microglial ROS production and
death [365].
The TCA enzymes located in the mitochondrial matrix, parti-
cularly aconitase, are sensitive to oxidant-mediated inactivation
[366]. Consequently, aconitase inactivation is often used as a
marker for mitochondrial oxidant stress. Aconitase has also been
proposed as a source of ROS [290,298]. The enzyme contains an
iron-sulfur cluster in its active site, which can be disassembled
upon exposure to O2
·−/H2O2, releasing free Feþ þ and H2O2 to
generate hydroxyl radicals via Fenten chemistry [367,368]. An
assessment of aconitase stability and activity in intact mitochon-
dria isolated from hearts subjected to 30 min coronary occlusion
followed by reperfusion has revealed a reduction in aconitase ac-
tivity, with no evidence of disassembly of the iron-sulfur cluster or
degradation of the enzyme [369]. These ﬁnding do not preclude a
possible role for aconitase-derived oxidants in I/R injury after
longer durations (430 min) of ischemia.
Irrespective of the source, the net production of ROS by mi-
tochondria is determined by the relative rates of ROS generation
(Fig. 6) and scavenging (Fig. 7) [300,304]. O2
·− is dismutated to H2O2
by the SOD isoenzymes; Mn–SOD in the matrix and CuZn–SOD in
the inner membrane space and cytosol. H2O2 is converted to H2O
by the glutathione peroxidase (GPx) and peroxiredoxin (Prx)/
thioredoxin (Trx) systems. Both of these thiol-based scavenging
systems are dependent on a reducing environment maintained by
a high NADPH/NADPþ ratio. The generation NADPH from NADPþ
is, in turn, dependent on several mitochondrial enzymes, such as,
NADP-transhydrogenase (NNT), which converts NADP to NADPH
(Fig. 7). Interestingly, both electron transport through the ETC
(increased potential for ROS production) and the activity of NNT
(increased anti-oxidant status) are dependent on NADH (e.g.,
Krebs cycle). It has been proposed that this coupling minimizes net
ROS production by energized mitochondria that are generating
ATP; referred to as the “redox-optimized ROS balance” [306,370–
372]. In mitochondria isolated from I/R-challenged hearts, the re-
dox-optimized ROS balance is altered in favor of ROS production
[327]. During ischemia, the mitochondrial NADPH pool is de-
creased and does not recover upon reperfusion. Predictably,
Fig. 8. Hypoxia/reoxygenation (H/R): mitochondrial ROS-induced ROS release leading to cell death. (Panel A) H/R-induced increase in ROS and decrease in membrane
potential (Δψ) of a single mitochondria of a cardiomyocyte. Immediately upon reoxygenation there is an increase Δψ and gradual increase in ROS. Once a threshold level of
ROS is achieved, ROS generation increases sharply and Δψ falls precipitously. (Panel B) H/R-induced loss of Δψ and ROS in a network of mitochondria within a cardiomyocyte.
Numerous mitochondria that are completely depolarized (dark areas in upper panel) are associated with ROS production (green areas in lower panel). (Panel C) H/R-induced
cell death. Several hours after reoxygenation about 2/3 of the cardiomyocytes are dead. The number of cells dying after H/R is reduced by an inhibitor of MTP (cyclosporine A;
CSA). Adapted from Juhaszova et al. [382].
D.N. Granger, P.R. Kvietys / Redox Biology 6 (2015) 524–551 537mitochondrial ROS production is increased after I/R; a response
that is attributed to depletion of the thiol-based antioxidant pool
[327]. In addition, I/R challenge of thioredoxin reductase 2 deﬁ-
cient hearts enhances both mitochondrial and myocardial dys-
function; effects that are corrected by thiol supplementation [373].
Finally, the protection against I/R-induced cardiac arrhythmia and
infarction that is afforded by exercise has been attributed to en-
hanced glutathione reductase activity [374].
Of the numerous potential sources of mitochondrial ROS pro-
duction during I/R, the ETC appears to play a dominant role and
the most extensively studied [9,290,296,298,301]. The tendency of
various ETC complexes to generate ROS in response to ROS ex-
posure underlies the notion that mitochondrial ROS production is
a self-amplifying process. This ampliﬁcation of ROS production by
the ETC has been termed “ROS-induced ROS release” (RIRR)
[290,375–381]. Laser-excitation of cardiac mitochondria results in
a gradual increase in ROS production, and when a “threshold” level
is achieved, a rapid loss of Δψ and a burst in ROS production en-
sues [375,377]. The time required to reach threshold levels is in-
directly proportional to glutathione levels [375], indicating that
once the mitochondrial ROS scavenging mechanisms are over-
whelmed a burst of ROS production occurs [372]. A similar phe-
nomenon has been noted in cardiomyocytes exposed to hypoxia
followed by reoxygenation (Fig. 8) [382]. The coincidence of the
increased ROS production with the collapse of Δψ is inconsistent
with the prevailing view that ROS production increases ex-
ponentially with increases in Δψ (see inset in Fig. 6). The only
explanation that has been offered for the unexpected ﬁndings is
the induction of “extreme disequilibrium” by H/R [290]. Interest-
ingly, an analogous situation is noted when mitochondria are ex-
posed to uncoupling agents. As discussed above, uncoupling of the
ETC reduces Δψ and ROS production by mitochondria derived from
normal hearts, but not in mitochondria from hearts subjected to I/
R [327].
Since the mitochondria in cardiomyocytes are arranged in a
three-dimensional lattice near the myoﬁlaments, both the Δψ
depolarization and ROS production spread to adjacent mitochon-
dria within the myocyte after exposure to H/R (Fig. 8). The spread
of ROS from one mitochondrion to another is attributed to the
opening of pores/channels in the inner mitochondrial membrane,
which allows for inter-mitochondrial signaling. Both an inner
membrane anion channel (IMAC) and the mitochondrial perme-
ability transition pore (MPTP) have been implicated in RIRR within
mitochondrial networks [290,378]. These two channels appear to
operate sequentially; contingent on the thiol redox status of the
mitochondrial matrix and cytoplasm [383]. Moderate reductionsin the GSH/GSSG ratio open the IMAC, while more severe reduc-
tions open the MPTP [383]. Opening the IMAC is associated with
transient depolarizations that develop into sustained oscillations
in Δψ and ROS that spread within mitochondrial networks, even-
tually becoming a cell-wide phenomenon. In cardiomyocytes,
these oscillations in RIRR and Δψ induce abnormal electrical
events (e.g., action potential duration) [377] which can be linked
to arrhythmias in intact hearts subjected to various oxidant
stresses, including I/R [378,384,385]. Opening the MPTP is asso-
ciated with a more drastic and sustained depolarization, with the
eventual collapse of Δψ, a burst of ROS production, and ultimately
cell death (Fig. 8) [375]. There is a direct relationship between the
number of mitochondria exhibiting Δψ collapse/ROS production
and myocyte dysfunction/death [382,386,387]. Interestingly, a
variety of pharmaceutical agents shown to exert protection against
I/R-induced infarcts in brain and heart appear to increase the
threshold for ROS-induced MPTP opening [382].
In silico approaches incorporating in vivo and ex vivo data
predict that IMAC and MPTP work in tandem to initiate and pro-
pagate mitochondrial network excitability [388]. Speciﬁcally, the
model predicts that mild O2
·− transients elicit opening of IMAC and
oscillations in Δψ. Once the thiol-scavenging systems are over-
whelmed, there is a larger burst of O2
·−/H2O2, which opens the
MPTP and leads to more dramatic and sustained depolarizations
(and eventual collapse) of the Δψ and ultimately mitochondrial
(and eventually cellular) demise. However an alternative me-
chanism has been proposed for RIRR within mitochondrial net-
works that involve only one channel/pore, the MPTP. In this
scheme, the transient oscillatory O2
·− waves and Δψ transients are
attributed to reversible openings of the MPTP [290,389]. Again,
once the redox balance is tipped in favor of ROS, the MPTP opening
remains stable resulting in propagation of the redox and Δψ waves
throughout the mitochondrial networks [290].
A major obstacle to identifying the speciﬁc channels/pores by
which RIRR is transmitted throughout the mitochondrial network
is uncertainty about the molecular identity of the MPTP [390,391]
and IMAC [377]. Current bias favors the F-ATP synthase (complex
V) as a major component of the MPTP [392], while the molecular
structure of the IMAC remains more ambiguous [290]. The current
approach used to determine the contribution of a particular
channel/probe largely relies on drugs that are assumed to speci-
ﬁcally target relevant structures and/or their modulators. Another
problem clouding this issue is the speciﬁcity of the probes used to
measure ROS waves or transients. Transient O2
·− generation by
mitochondria has been described in a variety of cell types and
these O2
·− “ﬂashes” are enhanced in cardiomyocytes challenged
with A/R [393]. However, it is unclear whether the probe is
Fig. 9. Monomeric and dimeric forms of NOS. (Panel A) NOS monomers can transfer electrons from NADPH to the ﬂavins in the reductase domain where limited amounts of
O2
·− can be formed. NOS monomers cannot bind the cofactor (BH4) or the substrate (arginine) and cannot generate NO. (Panel B) Formation of a NOS dimer requires heme,
which allows for the transfer of electrons from the reductase domain of one monomer to the oxidase domain of the adjacent monomer. When sufﬁcient arginine and BH4 are
present, NOS dimers couple their heme, allowing for O2 reduction and the synthesis of NO. From Forstermann and Sessa [396] where the structure and catalytic function of
NOS are discussed in greater detail.
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·− or pH transients [389,394]. Thus, a ﬁrmer under-
standing of the mechanisms involved in RIRR during I/R await the
development of probes that can accurately and speciﬁcally assess
transient O2
·− generation by mitochondria as well as identiﬁcation
of the structural equivalent of the relevant channel/pore.
3.1.4. Nitric oxide synthase (NOS)
There are three recognized isoforms of NOS, neuronal NOS
(nNOS), endothelial NOS (eNOS), and inducible NOS (iNOS)
[395,396]. In general, eNOS and nNOS are constitutively expressed,
while iNOS is inducible. As their designation implies, eNOS is
primarily expressed in endothelial cells and nNOS is primarily
localized to brain/neurons. However, their organ/cellular dis-
tribution is more ubiquitous, e.g., both nNOS and eNOS are present
in cardiomyocytes. Moreover, the subcellular localization of eNOS
and nNOS can change with cell activation [397]. Finally, while
iNOS is primarily induced in immune cells, such as macrophages,
its expression can be increased in diverse cell populations and
tissues [396,398]. The existence of a mitochondrial NOS isoform
(mtNOS) has been proposed, but this is still debated [295,399]. A
speciﬁc gene for mtNOS has not been identiﬁed and mitochondria-
associated NOS (when noted) may actually be one of the re-
cognized isoforms, e.g., nNOS or iNOS [400,401].
All NOS isoforms generate nitric oxide (NO) via the oxidation of
L-arginine. In general, eNOS and nNOS generate small amounts of
NO primarily for physiologic cell signaling, while iNOS produces
larger amounts that have potentially detrimental (e.g., cytotoxi-
city) consequences for target cells/tissues. NO, either derived from
eNOS (or nNOS) or exogenously administered as pharmaceutical
NO-donors, appears to be protective against I/R-induced injury in
different organs of experimental animals [402–406] and humans
[407]. The general consensus is that NO is protective in IR by virtue
of its anti-oxidant (neutralization of O2
·−) and anti-inﬂammatory
(inhibition of neutrophil adhesion/emigration) [406,408,409]
properties. Some of the ﬁndings that appear to disagree with the
beneﬁcial effects of NO in I/R have been attributed, in part, to mis-
localization and timing of the NO supplementation [410]. In ad-
dition, the beneﬁcial effects of NOS activity can be negated (or
even reversed) when NOS is converted to a O2
·− generating enzyme;
the net result is a reduction in cellular NO with a concomitant
increase in O2
·− [395,396,411,412]. This enzymatic conversion is
referred to as NOS uncoupling and it has been implicated in I/R-
induced ROS generation.
All NOS isoforms contain both an oxygenase and reductase
domain (Fig. 9) [395,396]. The reductase domain contains the
ﬂavins (FAD and FMN) and binds NADPH, while the oxygenasedomain contains heme and tetrahydrobiopterin (BH4) and binds
arginine. Arginine serves as the substrate, O2 and NADPH as co-
substrates, while BH4 serves as a cofactor (Fig. 9B). Normally,
electrons from NADPH are transferred through the reductase do-
main (via ﬂavins) to the prosthetic heme in the oxidase domain. O2
binds to the heme and is reduced to form a ferrous–dioxygen
complex; a step facilitated by BH4. This activation of O2 allows for
arginine oxidation and results in the formation of NO and citrul-
line. Thus, O2 reduction at the heme catalytic site is normally
coupled to the generation NO [395,396,411]. When electron ﬂow
to O2 is “uncoupled” from arginine oxidation, the reduced O2 is
released from the heme as O2
·−. NOS uncoupling can involve
structural (dimer disassembly) and/or functional (insufﬁcient co-
factors) alterations of the enzyme. While the uncoupling of NOS
can be demonstrated with each of the three isomers, the patho-
logic consequences of eNOS uncoupling has received the most
attention.
NOS is present in cells either as a monomer or homodimer. The
dimer couples O2 reduction to the synthesis of NO because the
transfer of electrons occurs in trans from the reductase of one
monomer to the oxygenase of the adjacent monomer. The
monomer in isolation cannot couple O2 reduction to NO synthesis
and generates O2
·− instead [395,396]. Since the activity of NOS as a
monomer is relatively weak, only small amounts of O2
·− are most
likely formed [395]. However, the net result may not be incon-
sequential, i.e., a decrease in cellular NO with a concomitant in-
crease in O2
·− would favor ROS-induced damage to cellular con-
stituents. It has been argued that once a dimer is formed it is re-
latively stable and signiﬁcant reversal to the monomeric form is
unlikely to occur in vivo [395]. This contention is supported by the
observation that, in a cell-free system or in isolated endothelial
cells, NOS uncoupling and O2
·− production can occur in the absence
of any dimer conversion to monomers [413]. However, in both
in vivo and in vitro models of I/R the dimer/monomer ratio falls
and can be rescued by maneuvers that re-couple NOS and prevent
I/R injury [414,415]. Regardless of the relative importance of dimer
disassembly, signiﬁcant functional uncoupling of NOS can occur
when either substrates or cofactors are limiting.
BH4, a NOS cofactor required for NO synthesis and release
[411,416], is synthesized from GTP via a pathway in which GTP
cyclohydrolase I (GTPCH) is the rate-limiting enzyme; cellular BH4
levels are directly correlated with GTPCH protein [417]. A strict
stoichiometric relationship between BH4 and eNOS dictates whe-
ther NOS is predominatly a NO or O2
·− generating enzyme
[411,416,418]. Decreases in the local BH4/NOS ratio increase the
probability of NOS producing O2
·− [411,419]. Thus, simply increasing
Fig. 10. Role of BH4 in NOS uncoupling in endothelial cells during H/R in vitro (Panels A–C) and I/R-induced cardiac injury in vivo (Panel D). (Panel A) Intracellular O2
·−
production (DHE-derived ﬂuorescence intensity) is increased in endothelial cells subjected to H/R. *po0.002 vs control (normoxia). (Panel B) BH4 decreases while BH2
increases in endothelial cells subjected to H/R. *po0.004 vs control (normoxia). (Panel C) NO production by endothelial cells is decreased during H/R and is partially rescued
by BH4 supplementation. *po0.002 vs control (normoxia) #po0.002 vs H/R. (Panel D) Liposomal BH4 (6R BH4) reduces myocardial infarction (as percent of area at risk;
AAR) in rat hearts subjected to I/R. Control represents I/R and vehicle represents empty liposome. *po0.001 vs control. Panels A–C modiﬁed from De Pascali et al. [423] while
panel D modiﬁed from Xie et al. [508].
D.N. Granger, P.R. Kvietys / Redox Biology 6 (2015) 524–551 539eNOS protein levels in endothelial cells either as a result of in-
creasing shear stress [420] or overexpression of eNOS [419]
without concomitant increases in GTPCH protein/activity and BH4
leads to NOS uncoupling, i.e., decrease in dimer/monomer ratio
and O2
·− production [419,420]. However, oxidative stress (e.g., I/R)
decreases cellular BH4 levels, reﬂecting the oxidation of BH4 to BH2
[411,416]. BH2 can occupy the BH4 binding site on NOS, but it is not
catalytically active, resulting in NOS uncoupling. Thus, in response
to oxidative stress, a positive feedback loop can be initiated in
which O2
·− production by uncoupled NOS leads to further BH4
oxidation to BH2 and the propagation of NOS uncoupling (analo-
gous to mitochondrial RIRR). In the face of this stress, cells are
capable of maintaining BH4 levels by recycling BH2 to BH4 via di-
hydrofolate reductase (DHFR) [421]. Based on these responses, it is
proposed that the ratio of BH4 to BH2 plays a more important role
in maintaining NOS coupling than the absolute level of BH4 [421].
The impact of BH4 levels on NOS uncoupling has been assessed
in both in vitro and in vivo models of I/R. BH4 content and NOS
activity in isolated rat hearts subjected to ischemia fall in parallel
and these changes are accompanied by large increases in NOS-
derived O2
·− production [422]. A reduction in the BH4/BH2 ratio and
NOS uncoupling has also been noted in an in vitro model of I/R
(Fig. 10) [423]. The I/R-induced reduction in BH₄ has been attrib-
uted to O2
·− generated by either xanthine oxidase [423] or NADPH
oxidase [424]. BH4 supplementation can re-couple NOS andameliorate the I/R-induced cardiac inﬂammation and tissue da-
mage [414,425–427]. BH4 supplementation, either directly or via
over-expression of GTPCH, is also effective in preventing cardio-
myocyte or endothelial cell cytotoxicity in in vitro models of A/R
[415,423,426]. Similarly, substrates for BH4 synthesis (sepiaterin
and folate) have been shown to protect against I/R-induced myo-
cardial inﬂammation and contractile dysfunction [428,429]. Simi-
lar observations have been noted in I/R models in the kidney [430],
liver [431], and skeletal muscle [432]. Finally, if BH4 levels are
reduced and eNOS is uncoupled prior to I/R, the resultant injury
responses in both liver and heart are exacerbated [433].
Arginine, serving as the nitrogen donor, is required for the
synthesis of NO by NOS. Arginine is also a substrate for arginase
present in mammalian tissues in two isoforms, arginase I and II
[434,435]. Arginase I is a cytosolic enzyme that generates urea for
detoxiﬁcation of ammonia and, while primarily localized in he-
patocytes, is also present in other cell types (e.g., endothelium,
cardiomyocyte, and vascular smooth muscle). Arginase II is a
ubiquitously expressed mitochondrial enzyme that generates or-
nithine, the precursor to polyamines that are involved in cell
proliferation, stress responses, and general maintenance. Since the
two isoforms share close to 60% homology [434,435], isoform-
speciﬁc inhibitors are lacking [435,436]. This makes it difﬁcult to
ascribe a role for either isoform and thus herein both isoforms will
simply be referred to as arginase.
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consume an amount of arginine that is sufﬁcient to limit NO
production by NOS [396,416,434,435]. This “arginine steal” me-
chanism not only decreases NO production but also increases O2
·−
generation by uncoupling NOS. After reperfusion of ischemic liver
[437] or heart [434,438,439], arginase activity increases, arginine
levels and NO production decrease, and O2
·− generation increases,
providing support for an “arginine steal” mechanism of NOS un-
coupling. Pharmacologic inhibition of arginase or arginine sup-
plementation restores the ability of NOS to generate NO and
ameliorates various indices of tissue injury. Endothelium-depen-
dent vasodilation is impaired by I/R in porcine coronary arteries
[440] and in the radial arteries of patients with coronary artery
disease [441]; an effect that is ameliorated by arginase inhibition.
Finally, inhibition of arginase in blood-perfused, but not saline-
perfused, hearts has been shown to rescue I/R-induced myocardial
dysfunction [442]. When RBCs from wild type mice were used to
perfuse hearts from eNOS deﬁcient mice, arginase blockade was
effective in ameliorating the I/R-induced dysfunction. However,
when RBCs derived from eNOS deﬁcient mice were used in wild
type heart preparations, arginase blockade was not effective. These
observations suggest that RBCs contain functional eNOS, which
can signiﬁcantly increase NO bioactivity in the reperfused
myocardium.
There are conﬂicting reports concerning the importance of ar-
ginase in NOS uncoupling. For example, in liver, brain, and kidney,
arginase activity is not increased when measured 24 h after re-
perfusion [443,444]. This can be attributed, in part, to the biphasic
changes in arginase activity following I/R; there is a transient in-
crease in activity which returns to basal levels by 24 h of re-
perfusion [445–447], followed by a second increase in enzyme
activity days later [439,447,448]. Moreover, the “arginine steal”
mechanism does not appear to play an important role in NOS
uncoupling in kidney parenchyma; neither arginase administra-
tion [449,450] nor arginine supplementation [448] alters the
changes in renal histopathology and inﬂammation induced by I/R.
Whether this diminished capacity for an “arginine steal” is related
to the fact that the kidney is the predominant site of arginine
production in the body is unclear. Finally, in both rats and pigs,
administration of either arginine or BH4 alone, either prior to or at
the time of reperfusion, do not affect the extent of myocardial
infarction induced by I/R; infarct size was reduced only following
treatment with a combination of arginine and BH4 [451]. It was
proposed that arginine alone was ineffective because arginase
activity was increased by I/R. However, it is possible that the
combination of arginine and BH4 is required to effectively couple
NOS. Systemic administration of arginine/BH4 was shown to be
effective in the rat, but not in the pig, where intracoronary ad-
ministration was required for an effect [451]. This was attributed
to the 10-fold greater collateral ﬂow in the rat than pig, thus al-
lowing the systemically administered NOS couplers more ready
access to the area at risk than in the rat. From the above, it is
apparent that more work is warranted to clarify the role of argi-
nase in NOS uncoupling, keeping in mind the biphasic changes in
arginase activity, the species and route of administration of in-
hibitors, and the organ system under study.4. Interactions between ROS producing enzymes
Most studies addressing the role of oxidative stress in experi-
mental models of reperfusion injury have focused on (and im-
plicated) a single enzymatic source of ROS. However, there are
several reports that describe a similar protective effect of multiple
treatments that target different sources of ROS, such as mi-
tochondrial complex 1 (rotenone) xanthine oxidase (allopurinol)or Nox (apocynin) [268,452–456]. While the ability of the different
agents to each afford nearly complete protection in a model of I/R
injury may reﬂect some degree of non-speciﬁcity of the reagents, a
more likely explanation is redox signaling that enables ROS pro-
duced by one enzymatic source to activate and enhance ROS
production by a second source. The possibility of such interactions
between the four major sources of ROS that have been implicated
in I/R injury is supported by evidence that H2O2, a readily diffu-
sible primary or secondary product of all four enzymatic sources,
can act as an intracellular messenger that mediates ROS-induced
ROS production, thereby propagating its own accumulation within
cells [457]. The net result of such a signaling mechanism would be
a signiﬁcant ampliﬁcation of ROS production in response to a pro-
oxidative insult or condition. While it remains unclear whether
interactions between ROS sources does indeed make a quantita-
tively important contribution to the magnitude of the oxidative
stress elicited by I/R, there is ample evidence (summarized in
several recent reviews) [458–460] to suggest that ROS-induced
ROS production warrants attention in this ﬁeld of investigation.
Some noteworthy examples of the interactions that may occur
between ROS sources after I/R are brieﬂy discussed below.
Interactions between Nox and mitochondria have been ex-
tensively studied. This work has revealed that NADPH oxidase
(Nox-1 or -2) activation can lead to enhanced mitochondrial ROS
(mtROS) formation via a signaling mechanism that involves Nox-
derived hydrogen peroxide activating ATP sensitive Kþ channels
in the mitochondrial membrane and opening the MPTP, with the
subsequent release of mtROS into the cytosol [461]. Similarly, an
enhancement of mtROS production elicited by hypoxia has been
shown to activate Nox via a protein kinase C dependent me-
chanism that yields the phosphorylation of cytosolic Nox subunits
and their subsequent translocation to the cell membrane
[460,462]. The two-way interactions, or cross-talk, between mi-
tochondria and Noxs has given rise to the concept that activation
of one enzymatic source of ROS can activate other sources and a
vicious cycle of enhanced cellular ROS production in response to
stimuli such as I/R. The critical role of mitochondrial ROS in such a
signaling process that ampliﬁes cellular ROS production in re-
sponse to either angiotensin II [463] or hypoxia [462] is supported
by studies that have employed targeted over-expression or in-
hibition of either MnSOD or glutathione peroxidase in mitochon-
dria. Furthermore, it has been demonstrated that depletion of
mitochondrial SOD (MnSOD) enhances Nox activity, while MnSOD
overexpression blunts the activation of Nox [463].
Enhanced mitochondrial ROS production has also been linked
to the conversion of XDH to XO in a rat model of volume overload
(VO) induced heart failure [464]. The study revealed that XO in-
hibition with allopurinol attenuates the mitochondrial dysfunction
that is associated with VO and that cyclic stretch of cardiomyo-
cytes activates XO through a mechanism dependent on mi-
tochondrial ROS. These ﬁndings are consistent with a self-perpe-
tuating cycle by which activated XO produces ROS that damage
mitochondria, that in turn causes further ROS production and XO
activation [464].
While there is considerable evidence (described above) that
implicates XO-derived ROS in the recruitment and activation of
leukocytes, less is known about the potential for leukocyte-asso-
ciated Nox to activate endothelial cell XO and vice verse. The po-
tential for such an interaction is supported by studies demon-
strating that activated adherent neutrophils elicit the conversion
of XDH to XO in endothelial cells and induce endothelial cell injury
via a XO dependent mechanism [465–467]. Activated leukocytes,
when ﬁrmly adherent to endothelial cells, result in a signiﬁcant
increase in the intracellular concentration of H2O2, of which ap-
proximately 60% is derived from the leukocyte and 40% from en-
dothelial cell XO [467]. The possibility that neutrophil (Nox)-
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the activated neutrophils with antioxidant enzymes (SOD, cata-
lase), which failed to confer protection. Similarly, exposure of en-
dothelial cells to relevant concentrations of exogenous H2O2 failed
to recapitulate the responses elicited by activated neutrophils
[465]. However, some reports have attributed the neutrophil-
mediated XDH to XO conversion to neutrophil-derived elastase
[468], while other studies fail to implicate elastase, but invoke a
role for tyrosine kinase activation or increased intracellular cal-
cium in the endothelial cell response [466,467]. Consequently,
while the cross-talk between adherent activated neutrophils and
endothelial cell XO may not be explained by ROS-activated ROS
production, it appears to involve a mechanism of XO activation
that is related to some other chemical and/or physical signal
emanating from the leukocyte.
Nitric oxide synthase also appears to modulate the activation of
XO. The increased XO activity detected in pulmonary endothelial
cells exposed to hypoxia alone or H/R is signiﬁcantly enhanced
following treatment of the cells with a NOS inhibitor, while the
change in XO activity is blunted by L-arginine supplementation or
when the cells are exposed to NO donating agents, suggesting that
NO exerts an inhibitory inﬂuence on XO activity [469,470]. The
ability of NO to inactivate XO has also been demonstrated in in-
terferon gamma-stimulated macrophages [471]. While the precise
mechanism for this inhibitory action of NO on XO remains unclear,
the observed responses have been attributed to the binding of NO
to the iron moiety of XO or its sulfhydryl groups [469,471]. In the
presence of NOS uncoupling, an entirely different interaction be-
tween NOS and XO is observed. As described above, the xanthine
oxidase-mediated ROS produced by aortic endothelial cells ex-
posed to H/R results in both tetrahydrobiopterin depletion and
S-glutathionylation, which leads to eNOS uncoupling and further
ROS production [423]. A similar BH4 depletion dependent me-
chanism likely results when H/R initially elicits the production of
superoxide from either mitochondria or Nox [472]. Regardless of
the initial source of superoxide, the consequent increase in ROS
production by uncoupled NOS, when combined to reduced avail-
ability of NO for inactivation of XO-derived superoxide, would
result in a more profound oxidative stress in response to H/R.5. Summary and conclusions
Progress in the ﬁeld of reperfusion research has been rapid and
signiﬁcant over the past 3–4 decades. The concept that ROS are
produced at an accelerated rate in tissues subjected to I/R and that
the accumulation of ROS contributes to reperfusion injury is now
well established and supported by a large and growing body of
evidence. A large part of this progress can be attributed to con-
tinued improvement and reﬁnement of the technologies and ex-
perimental approaches used to characterize the tissue/cellular
responses to I/R, including mutant mice with an altered expression
of ROS-related proteins, reagents that selectively inhibit speciﬁc
enzymatic sources of ROS production, and more precise methods
for detection and quantiﬁcation of ROS production in intact living
tissue, cultured cell monolayers, and subcellular compartments
(e.g., mitochondria). As a result of these advancements and the
more widespread use of cell culture models, the ﬁeld has transi-
tioned from an early emphasis on the direct damaging effects of
ROS to a focus on molecular aspects of cell dysfunction resulting
from the activation of ROS-dependent signaling events that un-
derlie reperfusion injury.
Notable progress has been made in deﬁning the potential
contribution of different enzymatic sources of ROS production in
tissues/cells exposed to I/R (H/R). Early studies in this ﬁeld placed
emphasis on XO as a major source of ROS after I/R. However, therecognition that some tissues exhibit low to negligible expression/
activity of this enzyme provided the impetus to evaluate the
contribution of other potential ROS sources, including Nox and
mitochondria. Uncoupled NOS and other enzymes (see Table 2)
that were not extensively addressed in the narrative above have
also been ascribed a role in reperfusion injury. While there is
ample evidence in the literature to tentatively assign a dominant
role for speciﬁc sources of ROS production in certain tissues (e.g.,
XO in the XOR-rich intestine, mitochondria in the metabolically
active heart and brain), the available body of knowledge in this
ﬁeld does not yet justify deﬁnitive conclusions in this regard.
Drawing such conclusions are made all the more difﬁcult because
of the potential for extensive cross-talk between these enzymes
and their susceptibility to ROS-activated ROS production. The re-
lative contributions of the different enzymes to I/R-induced ROS
production in a given tissue is also likely to be inﬂuenced by the
physiologic status of the tissue, e.g., with inﬂamed tissues pro-
ducing a different pattern of enzyme involvement due to tran-
scriptional up-regulation of certain ROS-producing enzymes (e.g.,
XO, Nox, and NOS) by cytokines. Similarly, chronic conditions that
promote mitochondrial biogenesis (e.g., skeletal muscle following
aerobic exercise training) may also inﬂuence the relative roles of
the different enzymes to I/R-induced ROS production. The re-
cognition that there are redundant and interactive sources of ROS
that are activated in response to I/R is an important consideration
in future efforts to design novel therapies that are directed to-
wards targeting ROS to attenuate or prevent reperfusion injury.
Despite the long and growing list of clinical conditions that
have been linked to reperfusion injury (Table 1) and the expansive
literature that implicates ROS in this injury response, the clinical
beneﬁt of ROS-targeted therapies have largely proven to be absent
or very limited. [473] While clear explanations for the failure to
effectively extend the positive preclinical ﬁndings to the clinical
setting are not readily apparent, preclinical models that in-
adequately mimic the complexities of the human disease coun-
terpart is one likely explanation. In this regard, a notable deﬁ-
ciency in the ﬁeld of reperfusion research is the prevalence of
studies that focus on the injury response and underlying me-
chanisms in otherwise healthy animals. Epidemiological evidence
clearly demonstrates that individuals who are most likely to ex-
perience an ischemic episode have one or more risk factors (e.g.,
hypertension, hypercholesterolemia, obesity, diabetes, and cigar-
ette smoking) for cardiovascular disease. Each of these risk factors
is known to induce a low-grade pro-inﬂammatory and pro-oxi-
dative environment that renders tissues more vulnerable to the
deleterious effects of a secondary oxidative and inﬂammatory
stress such as I/R [474]. The few published studies that address the
responses to I/R in the presence of risk factor(s) have revealed a
more robust production of ROS and greater tissue damage fol-
lowing reperfusion, compared to the responses elicited by I/R in
the absence of the risk factor(s). However, it remains unclear
whether the relative contributions of the different ROS producing
enzymes to the I/R-induced oxidative stress differ due to the
presence or absence of a risk factor for cardiovascular disease.
While this limitation is not unique to the ﬁeld of reperfusion re-
search, it does offer a challenge for future investigators in this area
to reﬁne experimental models so that they more accurately mimic
the conditions that exist in most patients who experience re-
perfusion injury. Furthermore, this issue warrants more attention
in order to ensure that meaningful progress can be made towards
the translation of preclinical ﬁndings to the clinical setting, and for
the eventual discovery of novel ROS-directed drugs that can be
used to effectively treat reperfusion injury.
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